WO2019079469A1 - CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA - Google Patents

CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA Download PDF

Info

Publication number
WO2019079469A1
WO2019079469A1 PCT/US2018/056311 US2018056311W WO2019079469A1 WO 2019079469 A1 WO2019079469 A1 WO 2019079469A1 US 2018056311 W US2018056311 W US 2018056311W WO 2019079469 A1 WO2019079469 A1 WO 2019079469A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
membered
independently selected
membered heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/056311
Other languages
English (en)
French (fr)
Inventor
Brent Douty
Andrew W. Buesking
David M. Burns
Andrew P. Combs
Nikoo Falahatpisheh
Ravi Kumar Jalluri
Daniel Levy
Padmaja POLAM
Lixin Shao
Stacey Shepard
Artem SHVARTSBART
Richard B. Sparks
Eddy W. Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA202002916A priority Critical patent/UA128085C2/uk
Priority to IL295978A priority patent/IL295978B1/en
Priority to RS20211581A priority patent/RS62818B1/sr
Priority to PE2020000403A priority patent/PE20210169A1/es
Priority to KR1020247033485A priority patent/KR20240152947A/ko
Priority to SG11202003428VA priority patent/SG11202003428VA/en
Priority to CN201880081276.3A priority patent/CN111542526B/zh
Priority to CA3084589A priority patent/CA3084589A1/en
Priority to IL295978A priority patent/IL295978B2/en
Priority to EA202090969A priority patent/EA202090969A1/ru
Priority to HRP20211827TT priority patent/HRP20211827T1/hr
Priority to CR20210442A priority patent/CR20210442A/es
Priority to SI201830506T priority patent/SI3697789T1/sl
Priority to MA50398A priority patent/MA50398B1/fr
Priority to CN202311732701.XA priority patent/CN118063470A/zh
Priority to SM20210656T priority patent/SMT202100656T1/it
Priority to EP18797408.4A priority patent/EP3697789B1/en
Priority to PL18797408T priority patent/PL3697789T3/pl
Priority to EP21196484.6A priority patent/EP4006034A1/en
Application filed by Incyte Corp filed Critical Incyte Corp
Priority to LTEPPCT/US2018/056311T priority patent/LT3697789T/lt
Priority to ES18797408T priority patent/ES2902390T3/es
Priority to AU2018350980A priority patent/AU2018350980C1/en
Priority to MX2020003862A priority patent/MX2020003862A/es
Priority to JP2020521911A priority patent/JP7244504B2/ja
Priority to BR112020007593-0A priority patent/BR112020007593A2/pt
Priority to CR20200214A priority patent/CR20200214A/es
Priority to MDE20200857T priority patent/MD3697789T2/ro
Priority to KR1020207014142A priority patent/KR102717072B1/ko
Publication of WO2019079469A1 publication Critical patent/WO2019079469A1/en
Priority to IL273983A priority patent/IL273983B2/en
Priority to PH12020550442A priority patent/PH12020550442A1/en
Anticipated expiration legal-status Critical
Priority to JOJO/P/2020/0086A priority patent/JOP20200086B1/ar
Priority to CY20211101062T priority patent/CY1124814T1/el
Priority to JP2023036727A priority patent/JP7541594B2/ja
Priority to AU2023203088A priority patent/AU2023203088B2/en
Priority to AU2024287193A priority patent/AU2024287193A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention provides tertiary alcohol compounds that modulate the activity of phosphoinositide 3-kinases-gamma ( ⁇ 3 ⁇ ) and are useful in the treatment of diseases related to the activity of ⁇ 3 ⁇ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
  • ⁇ 3 ⁇ phosphoinositide 3-kinases-gamma
  • PI3Ks The phosphoinositide 3-kinases (PI3Ks) belong to a large family of lipid signaling kinases that phosphorylate phosphoinositides at the D3 position of the inositol ring (Cantley, Science, 2002, 296(5573): 1655-7). PI3Ks are divided into three classes (class I, II, and III) according to their structure, regulation and substrate specificity.
  • Class I PI3Ks which include ⁇ 3 ⁇ , ⁇ 3 ⁇ , ⁇ 3 ⁇ , and ⁇ 3 ⁇ , are a family of dual specificity lipid and protein kinases that catalyze the phosphorylation of phosphatidylinosito-4,5-bisphosphate (PIP2) giving rise to phosphatidylinosito-3,4,5-trisphosphate (PIP3).
  • PIP3 functions as a second messenger that controls a number of cellular processes, including growth, survival, adhesion and migration. All four class I PI3K isoforms exist as heterodimers composed of a catalytic subunit (pi 10) and a tightly associated regulatory subunit that controls their expression, activation, and subcellular localization.
  • ⁇ 3 ⁇ , ⁇ 3 ⁇ , and PI3K8 associate with a regulatory subunit known as p85 and are activated by growth factors and cytokines through a tyrosine kinase-dependent mechanism (Jimenez, et al., J Biol Chem., 2002, 277(44):41556-62) whereas
  • ⁇ 3 ⁇ associates with two regulatory subunits (plOl and p84) and its activation is driven by the activation of G-protein-coupled receptors (Brock, et al., J Cell Biol., 2003, 160(l):89-99).
  • PI3Koc and ⁇ 3 ⁇ are ubiquitously expressed.
  • ⁇ 3 ⁇ and PI3K8 are ubiquitously expressed.
  • ⁇ 3 ⁇ knock-out or kinase dead knock in mice are normal and fertile and do not present any overt adverse phenotypes.
  • ⁇ 3 ⁇ is required for GPCR ligand-induced PtdlNs (3,4,5)P3 production, chemotaxis and respiratory burst in neutrophils.
  • ⁇ -null macrophages and dendritic cell exhibit reduced migration towards various chemoattractants.
  • T-cells deficient in ⁇ 3 ⁇ show impaired cytokine production in response to anti-CD3 or Con A stimulation.
  • ⁇ 3 ⁇ working downstream of adenosine A3A receptor is critical for sustained degranulation of mast cells induced by FCsRI cross-linking with IgE.
  • ⁇ 3 ⁇ is also essential for survival of eosinophils (Ruckle et al., Nat. Rev. Drug Discovery, 2006, 5, 903-918)
  • ⁇ 3 ⁇ was shown to be important for recruitment of neutrophils and eosinopohils to airways and degranulation of mast cells (see e.g. Laffargue et al., Immunity, 2002, 16, 441-451; Prete et al., The EMBO Journal, 2004, 23, 3505-3515; Pinho et al., L. Leukocyte Biology, 2005, 77, 800-810; Thomas et al., Eur. J.
  • mice were largely protected in four different models of rheumatoid arthritis (CIA, oc-CII-IA, K/BxN serum transfer and TNF transgenic) and ⁇ 3 ⁇ inhibition suppressed the progression of joint inflammation and damage in the CIA and oc-CII-IA models (see e.g., Camps et al., Nat. Medicine, 2005, 11, 939-943; Randis et al., Eur. J.
  • AD Alzheimer's disease
  • ⁇ 3 ⁇ inhibition was shown to attenuate AP(l-40)-induced accumulation of activated astrocytes and microglia in the hippocampus and prevent the peptide-induced congnitive deficits and synaptic dysfunction in a mouse model of AD (Passos et al., Brain Behav. Immun. 2010, 24, 493-501).
  • ⁇ 3 ⁇ deficiency or inhibition also was shown to delay onset and alleviate symptoms in experimental autoimmune encephalomyelitis in mice, a mouse model of human multiple sclerosis, which is another form of neurodegeneration disease (see e.g., Rodrigues et al., J. Neuroimmunol. 2010, 222, 90-94; Berod et al., Euro. J. Immunol. 2011, 41, 833-844; Comerford et al., PLOS one, 2012, 7, e45095; Li et al., Neuroscience, 2013, 253, 89-99).
  • M2 macrophages promote tumor growth and progression by secreting immunosuppressive factors such arginase 1, which depletes the tumor microenvironment of arginine, thereby promoting T-cell death and NK cell inhibition (Schmidt et al., Cancer Res. 2012, 72 (Suppl 1: Abstract, 411; Kaneda et al., Cancer Res., 74 (Suppl 19: Abstact 3650)).
  • ⁇ 3 ⁇ may play a direct role in cancer cells.
  • ⁇ 3 ⁇ is reported to be required for signaling from the Kaposi's sarcoma-associated herpevirus encoded vGPCR oncogene and tumor growth in a mouse model of sarcoma (Martin et al., Cancer Cell, 2011, 19, 805-813).
  • ⁇ 3 ⁇ was also suggested to be required for growth of T- ALL (Subramanjam et al., Cancer Cell, 2012, 21, 459-472), PDAC and HCC cells (Falasca and Maffucci, Frontiers in Physiology, 2014, 5, 1-10).
  • ⁇ 3 ⁇ gene was found to contain second highest scoring predicted driven mutation (R839C) among the set of genes not previously identified as a driver in pancreatic cancer (Carter et al., Cancer Biol. Ther. 2010, 10, 582-587).
  • ⁇ 3 ⁇ deficiency also has been reported to offer protection to experimental animals in different cardiovascular disease models.
  • lack of ⁇ 3 ⁇ would reduce angiotension-evoked smooth muscle contraction and, therefore, protect mice from angiotension-induced hypertension (Vecchione et al., J. Exp. Med. 2005, 201, 1217-1228).
  • ⁇ 3 ⁇ inhibition provided potent
  • the present invention relates to, inter alia, compounds of Formula (I):
  • the present invention further provides pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a
  • the present invention further provides methods of inhibiting an activity of ⁇ 3 ⁇ kinase comprising contacting the kinase with a compound of Formula (I), or a
  • the present invention further provides methods of treating a disease or a disorder associated with abnormal ⁇ 3 ⁇ kinase expression or activity in a patient by administering to the patient a therapeutically effective amount of a compound of Formula (I), or a
  • the present invention further provides a compound of Formula (I), or a
  • the present invention further provides use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in any of the methods described herein.
  • Figure 1 shows an XRPD pattern for crystalline Form I of Example PL
  • Figure 2 shows the results of a DSC experiment for crystalline Form I of Example PI.
  • Figure 3 shows the results of a TGA experiment for crystalline Form I of Example
  • PL Figure 4 shows an XRPD pattern for crystalline Form II of Example P2.
  • Figure 5 shows the results of a DSC experiment for crystalline Form II of Example
  • Figure 6 shows the results of a TGA experiment for crystalline Form II of Example
  • Figure 7 shows an XRPD pattern for crystalline Form III in Example P3.
  • Figure 8 shows the results of a DSC experiment for crystalline Form III of Example
  • Figure 9 shows the results of a TGA experiment for crystalline Form III of Example
  • Figure 10 shows an XRPD pattern for crystalline Form I of Example P4.
  • Figure 11 shows the results of a DSC experiment for crystalline Form I of Example
  • Figure 12 shows an XRPD pattern for crystalline Form I of Example P5.
  • Figure 13 shows the results of a DSC experiment for crystalline Form I of Example
  • Figure 14 shows an XRPD pattern for crystalline Form II of Example P6.
  • Figure 15 shows the results of a DSC experiment for crystalline Form II of Example
  • Figure 16A shows the asymmetric crystalline unit of the hydrobromic acid salt, methanol solvent form of Example P7, with thermal ellipsoids drawn to the 30% probability level.
  • Figure 16B shows a crystalline unit of the hydrobromic acid salt of Example P7, with thermal ellipsoids drawn to the 30% probability level.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is N or CR 7 ;
  • X 4 , X 5 , and X 6 are not all N;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F or CI, wherein the haloalkyl is optionally substituted with 1 or 2 independently selected Y 2 substituents;
  • R 1 is selected from H, D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6- 10 membered aryl, C 3 -iocycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • Ci-6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl- of R 1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R b substituents;
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, halo, C1-5 alkyl, Ci-6 alkoxy, C2-5 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C 3 - 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl, OH, NO2, amino, Ci-6 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, Ci-6 alkylsulfinyl, Ci-6 alkyl
  • R 8 is selected from H, D, Ci-s alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-,
  • R 4 , R 5 , R 6 and R 7 substituents together with the ring atoms to which they attached form a 4-, 5-, 6-, or 7-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R b substituents;
  • each R 1 is independently selected from H, CN, OH, C1-4 alkyl, and alkoxy;
  • each Y 2 is independently selected from OH, NO2, CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, C 1-6 alkoxy -C 1-6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, Ci-6 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci-6 alkoxy carbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonylamino
  • each R b is independently selected from D, halo, Ci-s alkyl, C 2- 6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR c , SR C , NHOR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c
  • each R 9 is independently selected from D, halo, C1-5 alkyl, C 2- 6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, N0 2 , OR k , SR k , NHOR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k , NR k
  • each R c is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-,
  • R c substituents together with the nitrogen atom to which they attached form a 4-, 5-, 6-, or 7-membered heteroaryl or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R d substituents;
  • each R d is independently selected from D, halo, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR e , SR e , NHOR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e , NR e
  • each R e is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-s alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-
  • each R f is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • each R s is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R s is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents;
  • each R h is independently selected from OH, NO2, CN, halo, C1-5 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-s haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonyla
  • heterocycloalkyl-Ci-6 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR m , SR m , NHOR m , C(0)R m , C(0)NR m R m , C(0)OR m , OC(0)R m , OC(0)NR m R m , NHR m , NR m R m , m C(0)R m ,
  • each R m is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C 2- 6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R m is each optionally substituted with 1, 2, 3 or 4 independently selected R n substituents;
  • each R n is independently selected from D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,
  • each R° is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C 2- 6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R° is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is N or CR 7 ;
  • X 4 , X 5 , and X 6 are not all N;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F or CI, wherein the haloalkyl is optionally substituted with 1 or 2 independently selected Y 2 substituents;
  • R 1 is selected from H, D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6- 10 membered aryl, C 3 -iocycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, CD 3 , halo, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C 3 - 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl, OH, NO2, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, C1-5 alkylsulfin
  • R 8 is selected from H, D, Ci-s alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-,
  • R 4 , R 5 , R 6 and R 7 substituents together with the ring atoms to which they attached form a 4-, 5-, 6-, or 7-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R b substituents;
  • each R 1 is independently selected from H, CN, OH, C1-4 alkyl, and alkoxy;
  • each Y 2 is independently selected from OH, NO2, CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, C 1-6 alkoxy -C 1-6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, Ci-6 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci-6 alkoxy carbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonylamino
  • each R b is independently selected from D, halo, Ci-s alkyl, C 2- 6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR c , SR C , NHOR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c
  • each R 9 is independently selected from D, halo, C1-5 alkyl, C 2- 6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, N0 2 , OR k , SR k , NHOR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k , NR k
  • each R c is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-,
  • R c substituents together with the nitrogen atom to which they attached form a 4-, 5-, 6-, or 7-membered heteroaryl or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R d substituents;
  • each R d is independently selected from D, halo, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR e , SR e , NHOR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e , NR e
  • each R e is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-s alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-
  • each R f is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • each R s is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R s is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents;
  • each R h is independently selected from OH, NO2, CN, halo, C1-5 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-s haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonyla
  • heterocycloalkyl-Ci-6 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR m , SR m , NHOR m , C(0)R m , C(0)NR m R m , C(0)OR m , OC(0)R m , OC(0)NR m R m , NHR m , NR m R m , m C(0)R m ,
  • each R m is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C 2- 6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R m is each optionally substituted with 1, 2, 3 or 4 independently selected R n substituents;
  • each R n is independently selected from D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,
  • each R° is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C 2- 6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R° is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is N or CR 7 ;
  • X 4 , X 5 , and X 6 are not all N;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F or CI, wherein the haloalkyl is optionally substituted with 1 or 2 independently selected Y 2 substituents;
  • R 1 is selected from H, D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6- 10 membered aryl, C 3 -iocycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, CD 3 , halo, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C 3 - 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl, OH, NO2, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, C1-5 alkylsulfin
  • R 8 is selected from H, D, Ci-s alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-,
  • R 4 , R 5 , R 6 and R 7 substituents together with the ring atoms to which they attached form a 4-, 5-, 6-, or 7-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R b substituents;
  • each R 1 is independently selected from H, CN, OH, C1-4 alkyl, and alkoxy;
  • each Y 2 is independently selected from OH, NO2, CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, C 1-6 alkoxy -C 1-6 alkyl, C3-10 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, Ci-6 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci-6 alkoxy carbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonylamino
  • each R b is independently selected from D, halo, Ci-s alkyl, C 2- 6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR c , SR C , NHOR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c
  • each R 9 is independently selected from D, halo, C1-5 alkyl, C 2- 6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, N0 2 , OR k , SR k , NHOR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k , NR k
  • each R c is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-,
  • each R d is independently selected from D, halo, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR e , SR e , NHOR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e , NR e C(0)OR
  • each R e is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-s alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-
  • each R f is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R s is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents;
  • each R h is independently selected from OH, NO2, CN, halo, C1-5 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonylamin
  • heterocycloalkyl-Ci-6 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR m , SR m , NHOR m , C(0)R m , C(0)NR m R m , C(0)OR m , OC(0)R m , OC(0)NR m R m , NHR m , NR m R m , m C(0)R m ,
  • each R m is independently selected from H, D, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocy cloalkyl-Ci-6 alkyl- of R m is each optionally substituted with 1, 2, 3 or 4 independently selected R n substituents;
  • each R n is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • each R° is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cy cloalky l-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocy cloalky l-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cy cloalky l-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocy cloalkyl-Ci-6 alkyl- of R° is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5
  • X 6 is N or CR 6 ;
  • X 7 is N or CR 7 ;
  • X 4 , X 5 , and X 6 are not all N;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F or CI, wherein the haloalkyl is optionally substituted with 1 or 2 independently selected Y 2 substituents;
  • R 1 is selected from H, D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6- 10 membered aryl, C 3 -iocycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci -6 alkyl-, CN, N0 2 , OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NR a R a , NR ⁇ R ⁇ 3 ,
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, halo, Ci-6 alkyl, Ci-6 alkoxy, C2-5 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, Ci-e haloalkoxy, 6-10 membered aryl, C 3 -10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl, OH, NO2, amino, Ci-6 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, Ci-6 alkylsulfinyl, Ci-6 alky
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each optionally substituted with 1, 2, 3, or 4 independently selected R h substituents;
  • R is selected from H, D, Ci-s alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl,
  • R 4 , R 5 , R 6 and R 7 substituents together with the ring atoms to which they attached form a 4-, 5-, 6-, or 7-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R b substituents;
  • each R 1 is independently selected from H, CN, OH, C1- alkyl, and CI alkoxy;
  • each Y 2 is independently selected from OH, NO2, CN, halo, Ci-s alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-s haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, C 1-6 alkoxy -C 1-6 alkyl, C3-10 cycloalkyl, C1-5 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci-6 alkylcarbonyl, C1-5 alkoxy carbonyl, Ci-6 alkylcarbonylamino, Ci- 6 alkylsulfony
  • heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, 3, or 4
  • each R b is independently selected from D, halo, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR c , SR C , NHOR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c ,
  • each R 9 is independently selected from D, halo, C1-5 alkyl, C 2- 6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, N0 2 , OR k , SR k , NHOR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k , NR k
  • each R c is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-,
  • heterocycloalkyl-Ci-6 alkyl- of R c is each optionally substituted with 1, 2, 3, or 4
  • each R d is independently selected from D, halo, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR e , SR e , NHOR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R
  • each R e is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-s alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-
  • each R f is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • each R s is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-s alkyl, C2-6 alkenyl, C 2 - 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alky
  • each R h is independently selected from OH, NO2, CN, halo, C1-5 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-ehaloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonylamino
  • heterocycloalkyl-Ci-6 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR m , SR m , NHOR m , C(0)R m , C(0)NR m R m , C(0)OR m , OC(0)R m , OC(0)NR m R m , NHR m , NR m R m , m C(0)R m ,
  • each R m is independently selected from H, D, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocy cloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocy cloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocy cloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocy cloalkyl-Ci-6 alkyl- of R m is each optionally substituted with 1, 2, 3 or 4 independently selected R n substituents;
  • each R n is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocy cloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, 4-7 membered heterocycloalkyl-Ci -6 alkyl-, CN, N0 2 , OR 0 , SR°, NHOR 0 , C(0)R°, C(0)NR°R°, C(0)OR°, OC(0)R°, OC(0)NR°R°, NR°R°, NR°C(0)R°, NR°C(0)OR°,
  • each R° is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocy cloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocy cloalkyl-Ci-6 alkyl- of R° is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6
  • X 7 is N or CR 7 ;
  • X 4 , X 5 , and X 6 are not all N;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F or CI, wherein the haloalkyl is optionally substituted with 1 or 2 independently selected Y 2 substituents;
  • R 1 is selected from H, D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, halo, C1-5 alkyl, Ci-6 alkoxy, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, C 1-6 haloalkoxy, 6-10 membered aryl, C 3 - 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-,
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each optionally substituted with 1, 2, 3, or 4 independently selected R h substituents;
  • R 8 is selected from H, D, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, C 1-6 haloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, 6-10 membered aryl-Ci- 6 alkyl-, C3-iocycloalkyl-Ci- 6 alkyl-,
  • R 4 , R 5 , R 6 and R 7 substituents together with the ring atoms to which they attached form a 4-, 5-, 6-, or 7-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R b substituents;
  • each R 1 is independently selected from H, CN, OH, C1- alkyl, and CI alkoxy;
  • each Y 2 is independently selected from OH, NO2, CN, halo, Ci-s alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-s haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, C 1-6 alkoxy -C 1-6 alkyl, C3-10 cycloalkyl, C1-5 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci-6 alkylcarbonyl, C1-5 alkoxy carbonyl, Ci-6 alkylcarbonylamino, Ci- 6 alkylsulfony
  • heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, 3, or 4
  • each R b is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci- 6 alkyl-, 4-10 membered heterocycloalkyl-Ci- 6 alkyl-, CN, NO 2 , OR c , SR C , NHOR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR
  • each R 9 is independently selected from D, halo, Ci-6 alkyl, C 2- 6 alkenyl, C2-6 alkynyl,
  • each R c is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10
  • heterocycloalkyl-Ci-6 alkyl- of R c is each optionally substituted with 1, 2, 3, or 4
  • R c substituents together with the nitrogen atom to which they attached form a 4-, 5-, 6-, or 7-membered heteroaryl or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R d substituents;
  • each R d is independently selected from D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci- 6 alkyl-, 5-10 membered heteroaryl-Ci- 6 alkyl-, 4-10 membered heterocycloalkyl-Ci- 6 alkyl-, CN, NO 2 , OR e , SR e , NHOR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e , NR
  • each R e is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 member
  • each R f is independently selected from D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • each R s is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C 2- 6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R s is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents;
  • each R h is independently selected from OH, NO2, CN, halo, C1-5 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonylamin
  • heterocycloalkyl-Ci-6 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR m , SR m , NHOR m , C(0)R m , C(0)NR m R m , C(0)OR m , OC(0)R m , OC(0)NR m R m , NHR m , NR m R m , ⁇ , NR m C(0)
  • each R m is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-s alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-
  • each R n is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • each R° is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalky l-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R° is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is N or CR 7 ;
  • X 4 , X 5 , and X 6 are not all N;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F or CI; R 1 is independently selected from H, D, halo, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci -6 alkyl-, CN, N0 2 , OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, halo, C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl, OH, NO2, amino, Ci-6 alkylamino, di(Ci-6 alkyl)amino, thio, Ci- 6 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfon
  • R 8 is selected from H, D, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl,
  • each R 1 is independently selected from H, CN, OH, Ci-4 alkyl, and alkoxy;
  • each R a is independently selected from H, D, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-
  • heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, 3, or 4
  • each R b is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO2, OR c , SR C , NHOR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c
  • each R 9 is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR k , SR k , NHOR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k , NR k C
  • each R c is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10
  • heterocycloalkyl-Ci-6 alkyl- of R c is each optionally substituted with 1, 2, 3, or 4
  • each R d is independently selected from D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, N0 2 , OR e , SR e , NHOR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e , NR e C(0)OR
  • each R e is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-;
  • each R h is independently selected from OH, N0 2 , CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfony
  • each R k is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is N or CR 7 ;
  • X 4 , X 5 , and X 6 are not all N;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F or CI, wherein the haloalkyl is optionally substituted with 1 or 2 independently selected Y 2 substituents;
  • R 1 is selected from H, D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6- 10 membered aryl, C 3 -iocycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, halo, C1-5 alkyl, Ci-6 alkoxy, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-e haloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci- 6 alkyl-, C3-io cycloalkyl-Ci- 6 alkyl-, 5-10 membered heteroaryl-Ci- 6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl, OH, NO2, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, C1-5 alkylsulfiny
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each optionally substituted with 1, 2, 3, or 4 independently selected R h substituents;
  • R 8 is selected from H, D, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, C 1-6 haloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl,
  • R 4 , R 5 , R 6 and R 7 substituents together with the ring atoms to which they attached form a 4-, 5-, 6-, or 7-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R b substituents;
  • each R 1 is independently selected from H, CN, OH, C 1- alkyl, and CI alkoxy;
  • each Y 2 is independently selected from OH, NO2, CN, halo, Ci-s alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-s haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, C 1-6 alkoxy -C 1-6 alkyl, C3-10 cycloalkyl, C1-5 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, C1-5 alkylsulfinyl, C1-5 alkylsulfonyl, carbamyl, Ci-s alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsul
  • heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, 3, or 4
  • each R b is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR c , SR C , NHOR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR
  • each R 9 is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR k , SR k , NHOR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k , NR k C(0)
  • each R c is independently selected from H, D, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-,
  • heterocycloalkyl-Ci-6 alkyl- of R c is each optionally substituted with 1, 2, 3, or 4
  • each R d is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR e , SR e , NHOR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e , NR e C
  • each R e is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-s alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-
  • each R f is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • each R s is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C 2- 6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R s is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents;
  • each R h is independently selected from OH, N0 2 , CN, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, Ci-6 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6
  • each R k is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10
  • heteroaryl 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10 cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl- and 4-10 membered
  • heterocycloalkyl-Ci-6 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected from D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci- 6 alkyl-, 5-10 membered heteroaryl-Ci- 6 alkyl-, 4-10 membered heterocycloalkyl-Ci- 6 alkyl-, CN, NO 2 , OR m , SR m , NHOR m , C(0)R m , C(0)NR m R m , C(0)OR m , OC(0)R m , OC(0)NR m R m , NHR m , NR m R m , m C(0)R m
  • each R m is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C 2- 6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R m is each optionally substituted with 1, 2, 3 or 4 independently selected R n substituents;
  • each R n is independently selected from D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • each R° is independently selected from H, D, Ci-6 alkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C 2- 6 alkenyl, C 2- 6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl- and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R° is each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is N or CR 7 ;
  • X 4 , X 5 , and X 6 are not all N;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F or CI;
  • R 1 is independently selected from H, D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci -6 alkyl-, CN, N0 2 , OR a , SR a , NHOR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NR a R a , NR ⁇ R ⁇ 3 , NR a C
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, halo, C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-e haloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C 3 -io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl, OH, NO2, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, Ci- 6 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkyls
  • R 8 is selected from H, D, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl,
  • each R 1 is independently selected from H, CN, OH, C1- alkyl, and CI alkoxy;
  • each R a is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-
  • heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, 3, or 4
  • each R b is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, NO 2 , OR c , SR C , NHOR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR
  • each R 9 is independently selected from D, halo, Ci-6 alkyl, C 2- 6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, N0 2 , OR k , SR k , NHOR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k , NR k C(0)
  • each R c is independently selected from H, D, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-10
  • heterocycloalkyl-Ci-6 alkyl- of R c is each optionally substituted with 1, 2, 3, or 4
  • each R d is independently selected from D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-io cycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, 4-10 membered heterocycloalkyl-Ci-6 alkyl-, CN, N0 2 , OR e , SR e , NHOR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e , NR e C
  • each R e is independently selected from H, D, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C 3 -7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-;
  • each R h is independently selected from OH, NO2, CN, halo, C1-5 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-s haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-ehaloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonylamin
  • each R k is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C3-iocycloalkyl-Ci-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl-.
  • X 2 is N
  • X 2 is CR 2 .
  • R 2 is selected from H, D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-5 haloalkyl.
  • R 2 is selected from H, D, and C1-5 alkyl.
  • R 2 is H.
  • X 2 is N or CH.
  • R 3 is H or D.
  • R 3 is H.
  • X 4 is CR 4 .
  • R 4 is selected from H, D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-5 haloalkyl.
  • R 4 is selected from H, D, halo and C1-5 alkyl.
  • R 4 is selected from H, D, fluoro, methyl, and CD 3 .
  • R 4 is selected from H, fluoro, methyl, and CD 3 . In some embodiments, R 4 is selected from H, fluoro, and methyl.
  • X 4 is N.
  • X 5 is CR 5 .
  • R 5 is selected from H, D, halo, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-5 haloalkyl.
  • R 5 is selected from H, D, and C1-5 alkyl.
  • R 5 is H.
  • X 5 is N.
  • X 5 is N or CH.
  • X 6 is CR 6 .
  • R 6 is selected from H, D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-5 haloalkyl.
  • R 6 is selected from H, D, and halo.
  • R 6 is selected from H and halo.
  • R 6 is selected from H and fluoro.
  • X 6 is N.
  • X 7 is CR 7 .
  • R 7 is selected from H, D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-5 haloalkyl.
  • R 7 is selected from H, D, and C1-5 alkyl.
  • R 7 is H.
  • X 7 is N.
  • X 7 is N or CH.
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, halo, CN, Ci-s alkyl, and C1-5 haloalkyl.
  • R 4 , R 5 , R 6 , and R 7 are each independently selected from H, D, halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-5 haloalkyl.
  • R 2 , R 3 , R 5 , and R 7 are each H.
  • R 3 , R 5 , and R 7 are each H.
  • any two R 4 , R 5 , and R 6 substituents, together with the ring atoms to which they attached form a 4-, 5-, 6-, or 7-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R b substituents.
  • R 1 is optionally substituted with 1, 2, 3, or 4 independently selected R b substituents
  • R 1 is selected from H, D, halo, Ci-s alkyl, C 2- 6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, OR a , C(0)R a , C(0)NR a R a , C(0)OR a , NR a R a , NR a C(0)R a , NR a C(0)OR a , NR a C(0)NR a R a , NR a S(0) 2 NR a R a , NR a S(0) 2 R a , S(0) 2 R a , and S(0) 2 NR a R a , wherein the C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, 6-10 membered aryl, C3-10 cycloalky
  • R 1 is selected from H, D, halo, C1-5 alkyl, C1-5 haloalkyl, 6-10 membered aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, OR a , C(0)NR a R a , and C(0)OR a , wherein the Ci -6 alkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R b substituents.
  • R 1 is selected from H, C1-5 alkyl, C1-5 haloalkyl, phenyl, 3-6 membered cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocycloalkyl,
  • C(0)NR a R a C(0)OR a
  • the C1-5 alkyl, phenyl, 3-6 membered cycloalkyl, 5-6 membered heteroaryl, and 5-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R b substituents.
  • R 1 is selected from H, C1-5 alkyl, C1-5 haloalkyl, phenyl, 5-6 membered heteroaryl, C(0)NR a R a , and C(0)OR a , wherein the C1-5 alkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R b substituents.
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4- triazolyl, and piperidinyl, wherein the phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4-triazolyl, and piperidinyl are each optionally substituted by 1 or 2 independently selected R b substituents.
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl, wherein the phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl are each optionally substituted by 1 or 2 independently selected R b substituents.
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4- triazolyl, and piperidinyl, wherein the phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4-triazolyl, and piperidinyl are each optionally substituted by 1 or 2 independently selected R b substituents; and each R a is selected from H, Ci-s alkyl, isoxazol-5-ylmethyl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, 5,6-d
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4- triazolyl, and piperidinyl, wherein the phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4-triazolyl, and piperidinyl are each optionally substituted by 1 or 2 independently selected R b substituents; and each R a is selected from H, Ci-s alkyl, and isoxazol-5-ylmethyl; wherein said isoxazol-5-ylmethyl is substituted by methyl and said Ci-s alkyl is optionally substituted
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl, wherein the phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl are each optionally substituted by 1 or 2 independently selected R b substituents; and each R a is selected from H, Ci-s alkyl, and isoxazol-5-ylmethyl; wherein said isoxazol-5-ylmethyl is substituted by methyl and said Ci-s alkyl is optionally substituted by OH.
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl, wherein the phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl are each optionally substituted by 1 or 2 independently selected R b substituents; and each R a is selected from H, Ci-s alkyl, isoxazol-5-ylmethyl, tetrahydrofuran- 3-yl, tetrahydro-2H-pyran-4-yl, 5,6-dihydro-4H-pyrrolo[l,2-b]pyrazol-3-yl, wherein said
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, cyclopropyl, thiazol-5-yl, thiazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, oxazol-5-yl, pyrimidin-5-yl, pyridin-3-yl, pyridin-4-yl, isoxazol-5-yl, 1,2,4-triazol-l-yl, and piperidin-l-yl, wherein the phenyl, thiazol-5-yl, thiazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, oxazol-5-yl, pyrimidin-5-yl, pyridin-3-yl, pyridin-4-yl, is
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, thiazol-5-yl, thiazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, oxazol-5-yl, pyrimidin-5-yl, pyridin-3-yl, pyridin-4-yl, isoxazol-5-yl, and 1,2,4-triazol-l-yl, wherein the phenyl, thiazol-5-yl, thiazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, oxazol-5-yl, pyrimidin-5-yl, pyridin-3-yl, pyridin-4-yl, isoxazol-5-yl, and 1,2,4-tria
  • R 1 is selected from H, methyl, CF 3 , C(0)OCH 3 , C(0)NHCH 3 , C(0)NHCH 2 -(3-methylisoxazol-5-yl), C(0)NHCH 2 C(CH 3 ) 2 OH, 4-fluorobenzamide-3-yl, 2- cyclopropylthiazol-5-yl, 5-methoxythiazol-2-yl, 2-(hydroxymethyl)pyridin-4-yl, l-(methyl- d 3 )-lH-pyrazol-5-yl, 2-methyloxazol-5-yl, l-methyl-lH-pyrazol-5-yl, pyrimidin-3-yl, 2- methoxypyridin-3-yl, 2-methylthiazol-5-yl, 3-fluoro-2-methylpyridin-4-yl, 1,5-dimethyl-lH- pyrazol-4-yl, 1 -methyl- lH-pyrazol-4-yl, l,
  • R 1 is selected from H, methyl, CF 3 , C(0)OCH 3 , C(0)NHCH 3 , C(0)NHCH 2 -(3-methylisoxazol-5-yl), C(0)NHCH 2 C(CH 3 ) 2 OH, 4-fluorobenzamide-3-yl, 2- cyclopropylthiazol-5-yl, 5-methoxythiazol-2-yl, 2-(hydroxymethyl)pyridin-4-yl, l-(methyl- d 3 )-lH-pyrazol-5-yl, 2-methyloxazol-5-yl, l-methyl-lH-pyrazol-5-yl, pyrimidin-3-yl, 2- methoxypyridin-3-yl, 2-methylthiazol-5-yl, 3-fluoro-2-methylpyridin-4-yl, 1,5-dimethyl-lH- pyrazol-4-yl, 1 -methyl- lH-pyrazol-4-yl, l,
  • R 1 is selected from H, methyl, CF 3 , C(0)OCH 3 , C(0)NHCH 3 , C(0)NHCH 2 -(3-methylisoxazol-5-yl), C(0)NHCH 2 C(CH 3 ) 2 OH, 4-fluorobenzamide-3-yl, 2- cyclopropylthiazol-5-yl, 5-methoxythiazol-2-yl, 2-(hydroxymethyl)pyridin-4-yl, l-(methyl- d 3 )-lH-pyrazol-5-yl, 2-methyloxazol-5-yl, l-methyl-lH-pyrazol-5-yl, pyrimidin-3-yl, 2- methoxypyridin-3-yl, 2-methylthiazol-5-yl, 3-fluoro-2-methylpyridin-4-yl, 1,5-dimethyl-lH- pyrazol-4-yl, 1 -methyl- lH-pyrazol-4-yl, l,
  • R 1 is selected from H, methyl, CF 3 , and
  • R 1 is CF 3 .
  • R 1 is C(0)NHCH 2 C(CH 3 ) 2 OH.
  • Y 1 is C1-5 haloalkyl, wherein each halogen is F, wherein the haloalkyl is optionally substituted with 1 or 2 independently selected Y 2 substituents.
  • Y 1 is selected from CF 3 , CCI3, CF 2 H, CC1 2 H, CF 2 Y 2 , CC1 2 Y 2 , CFH 2 , CC1H 2 , CFHY 2 , CC1HY 2 , CF(Y 2 ) 2 and CC1(Y 2 ) 2 .
  • Y 1 is selected from CF 3 , CF 2 H, CF 2 Y 2 , CFH 2 , CFHY 2 , and CF(Y 2 ) 2 .
  • Y 1 is C1-5 haloalkyl, wherein each halogen is F.
  • Y 1 is C1-5 haloalkyl, wherein each halogen is CI.
  • Y 1 is selected from CH 2 F, CHF 2 , CF 3 , and CF 2 CF 3 .
  • Y 1 is CF 3 .
  • Y 1 is CH 2 F.
  • Y 1 is CHF 2 .
  • Y 1 is CF 2 CF 3 .
  • Y 2 is selected from D, halo, C1-5 alkyl, and C1-5 haloalkyl.
  • Y 2 is selected from halo and Ci-s haloalkyl.
  • R 1 and Y 1 are CF 3 .
  • R 1 is selected from H, methyl, CF 3 , and C(0)NHCH 2 C(CH 3 ) 2 OH
  • Y 1 is selected from CH 2 F, CHF 2 , CF 3 , and CF 2 CF 3 .
  • R 1 is selected from H, methyl, and CF 3
  • Y 1 is selected from CH 2 F, CHF 2 , CF 3 , and CF 2 CF 3 .
  • R 1 is CF 3 and Y 1 is selected from CH 2 F, CHF 2 , CF 3 , and
  • R 1 is C(0)NHCH 2 C(CH 3 ) 2 OH and Y 1 is selected from CH 2 F, CHF 2 , CF 3 , and CF 2 CF 3 .
  • R 8 is selected from H, D, Ci-s alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, 6-10 membered aryl, C 3- io cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, and C(0)NR a R a , wherein the C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-ehaloalkoxy, 6-10 membered aryl, C 3- io cycloalkyl, 5- 10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 9 substituents.
  • R 8 is selected from H, D, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl,
  • R 8 is selected from H, C1-5 alkyl, 6-10 membered aryl, C 3- io cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, and C(0)NR a R a , wherein the C1-5 alkyl, 6-10 membered aryl, C 3- io cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 9 substituents.
  • R 8 is selected from H, C1-5 alkyl, 6-10 membered aryl, C 3- io cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-5 alkyl, 6-10 membered aryl, C 3- io cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 9 substituents.
  • R 8 is selected from H, C1-5 alkyl, phenyl, C 3 -6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, and C(0)NH 2 , wherein the C1-5 alkyl, phenyl, C 3- 6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R 9 substituents.
  • R is selected from H, Ci-s alkyl, phenyl, C3-5 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl, wherein the C1-5 alkyl, phenyl, C3- 6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R 9 substituents.
  • R 8 is selected from H, C1-5 alkyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and C(0)NH 2 , wherein the C1-5 alkyl, C3-6 cycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R 9 substituents.
  • R 8 is selected from H, C1-5 alkyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, wherein the C1-5 alkyl, C3-6 cycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R 9 substituents.
  • R 8 is selected from H, methyl, hydroxy methyl, ethyl, 1- hydroxyethyl, 2-hydroxyethyl, 2-aminoethyl, 2-( -methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H- pyran-4-yl ⁇ amino)ethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxpropyl, cyclopropyl, 1- methyl-lH-tetrazol-5-yl, and aminocarbonyl.
  • R 8 is selected from H, methyl, hydroxy methyl, ethyl, 1- hydroxyethyl, 2-hydroxyethyl, 2-aminoethyl, 2-( -methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H- pyran-4-yl ⁇ amino)ethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxpropyl, cyclopropyl, and 1 -methyl- lH-tetrazol-5-yl.
  • R 8 is selected from H, methyl, ethyl, 2-hydroxyethyl, 2- aminoethyl, 2-(N-methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, l-methyl-lH-tetrazol-5-yl, and aminocarbonyl.
  • R 8 is selected from H, methyl, ethyl, 2-hydroxyethyl, 2- aminoethyl, 2-(N-methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, and l-methyl-lH-tetrazol-5-yl.
  • R 8 is selected from H, methyl, hydroxymethyl, ethyl, 2- hydroxyethyl, 2-(N-methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, l-methyl-lH-tetrazol-5-yl, and amino carbonyl.
  • R 8 is selected from H, methyl, hydroxymethyl, ethyl, 2- hydroxyethyl, 2-(N-methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, and l-methyl-lH-tetrazol-5-yl.
  • R 8 is selected from H, methyl, ethyl, 2-hydroxyethyl, 2-(N- methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, 1-methyl-lH- tetrazol-5-yl, and aminocarbonyl.
  • R is selected from H, methyl, ethyl, 2-hydroxyethyl, 2-(N- methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, and 1-methyl- lH-tetrazol-5-yl.
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloalkyl or heterocycloalkyl group which is optionally substituted by 1 or 2 independently selected halo substituents.
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloalkyl or heterocycloalkyl group which is optionally substituted by 1 or 2 substituents independently selected from CI and F.
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloalkyl group which is optionally substituted by 1 or 2 substituents independently selected from CI and F.
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 2-fluorocyclopentyl group.
  • each R 9 is independently selected from halo, Ci-s alkyl, Ci-s haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-Ci-3 alkyl-, C3-6 cycloalkyl-Ci-3 alkyl-, 5-6 membered heteroaryl-Ci-3 alkyl-, 4-6 membered heterocycloalkyl-Ci -3 alkyl-, CN, OR k , C(0)R k , C(0)NR k R k , C(0)OR k , NR k R k , NR k C(0)R k , NR k C(0)OR k , NR k C(0)NR k R k , NR k S(0) 2 R k , NR k S(0) 2 NR k R k , S(0) 2 R k , and S(0) 2 NR
  • each R 9 is independently selected from halo, C1-5 alkyl, C1-5 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, OR k , C(0)R k , C(0)NR k R k , C(0)OR k , and NR k R k , wherein the Ci -6 alkyl, Ci -6 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl of R 9 is each optionally substituted with 1 or 2 independently selected R q substituents.
  • each R 9 is independently selected from halo, C1-5 alkyl, C1-5 haloalkyl, CN, OR k , and NR k R k ; wherein the C1-5 alkyl of R 9 is each optionally substituted with 1, 2, 3, or 4 independently selected R q substituents.
  • each R 9 is independently selected from halo, C1-5 alkyl, C1-5 haloalkyl, CN, OR k , and NR k R k ; wherein the C1-5 alkyl of R 9 is each optionally substituted with 1, or 2 independently selected R q substituents.
  • each R 9 is independently selected from Ci-s alkyl, OR k , and
  • each R 9 is independently selected from methyl, OH, N- methylamino, and N-(tetrahydropyran-4-yl)amino.
  • each R a is independently selected from H, D, Ci-s alkyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the Ci-s alkyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroary l-Ci-6 alkyl-, and 4-7 membered
  • heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, or 3 independently selected R b substituents.
  • each R a is independently selected from H, C1-5 alkyl, C1-5 haloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C1-5 haloalkyl, phenyl- Ci-s alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, or 3 independently selected R b substituents.
  • each R a is independently selected from H, C1-5 alkyl, C1-5 haloalkyl, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C1-5 haloalkyl, and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1 or 2 independently selected R b substituents.
  • each R a is selected from H, C1-5 alkyl, and isoxazol-5- ylmethyl; wherein said isoxazol-5-ylmethyl is substituted by methyl.
  • each R a is H.
  • each R b is independently selected from halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 memberedaryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, OR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c , NR c C(0)NR c R c , S(0)R c , S(0)NR c R c , S(0) 2 R c , and S(0) 2 NR c R c , wherein the C1-5 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, C3-10
  • each R b is independently selected from halo, C1-5 alkyl, C 2- 6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, OR c , C(0)R c , C(0)NR c R c , C(0)OR c , and NR C R C , wherein the Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R d substituents.
  • each R b is independently selected from halo, C1-5 alkyl, C3-6 cycloalkyl, OR c , and C(0)NR c R c , wherein the C1-5 alkyl and C3-6 cycloalkyl are each optionally substituted with 1 or 2 independently selected R d substituents selected from D, C1-5 alkyl and OH; and each R c group is independently selected from H and C1-5 alkyl.
  • each R b is independently selected from fluoro, methyl, CD 3 , hydroxymethyl, methoxy, C(0)NH 2 , cyclopropyl, and 3-methylisoxazol-5-yl.
  • each R c is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C 3 -7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocycloalkyl-Ci-4 alkyl-, wherein the Ci-s alkyl, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C 3 -7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alky
  • each R d is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, 4-7 membered heterocycloalkyl-Ci-6 alkyl-, OH, NO2, CN, halo, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, Ci-6 alkylsulfinyl, Ci-e alkylsulfonyl, carbamyl, C1-5 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, C1-5 alkoxycarbonyl, C1-5 alkylcarbonylamino, C1-5 alkylsulfonylamino, aminosulfonyl, Ci
  • each R f is independently selected from OH, NO2, CN, halo, Ci-s alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-s haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfony
  • each R c is independently selected from H, C1-5 alkyl, and C1-5 haloalkyl, wherein the C1-5 alkyl and C1-5 haloalkyl of R c is each optionally substituted with 1, 2, 3, or 4 independently selected R d substituents; and each R d is independently selected from D, halo, Ci-6 alkyl, C1-5 haloalkyl, OH, CN, Ci-6 alkoxy, Ci-e haloalkoxy, amino, C1-5 alkylamino, and di(Ci-6 alkyl)amino.
  • each R c group is independently selected from H and C1-5 alkyl; and each R d is independently selected from selected from D, C1-5 alkyl and OH.
  • two R c substituents together with the nitrogen atom to which they attached form a 4-, 5-, 6-, or 7-membered heteroaryl or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R d substituents.
  • two R c substituents together with the nitrogen atom to which they attached form a 5- or 6-membered heteroaryl or heterocycloalkyl group optionally substituted with 1 or 2 independently selected R d substituents.
  • two R c substituents together with the nitrogen atom to which they attached form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 independently selected R d substituents.
  • two R c substituents together with the nitrogen atom to which they attached form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 independently selected R d substituents selected from D and C 1-5 alkyl.
  • two R c substituents together with the nitrogen atom to which they attached form a 5- or 6-membered heterocycloalkyl group optionally substituted with methyl.
  • each R k is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocycloalkyl-Ci-4 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocycloalkyl-Ci- 4 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4 independently selected R q substituents;
  • each R q is independently selected from D, halo, Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, 4-7 membered heterocycloalkyl-Ci-6 alkyl-, OH, NO2, CN, halo, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, Ci-6 alkylsulfinyl, Ci-e alkylsulfonyl, carbamyl, C1-5 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, Ci-6 alkylsulfonylamino, aminosulfonyl, Ci- 6 al
  • each R n is independently selected from OH, NO2, CN, halo, C1-5 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci-6 alkylsulfinyl, Ci-6 alkylsulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, Ci- 6 alkylsulfonylamino, aminos
  • each R k is independently selected from H, C1-5 alkyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, alkyl-, C 3 -7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered
  • heterocycloalkyl-Ci-4 alkyl- wherein the C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci- 4 alkyl-, C 3 -7 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocycloalkyl-Ci-4 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected halo, C1-5 alkyl, C1-5 haloalkyl, OH, CN, C1-5 alkoxy, C 1-6 haloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, Ci-6 alkylsulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, C1-5 alkoxycarbonyl, Ci-e alkylcarbonylamino, C1-5 alkylsulfonylamino, aminosulfonyl, C1-5 alkylaminosulfonyl, and di(Ci- 6 alkyl)aminosulfonyl.
  • each R k is independently selected from H, C1-5 alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl, wherein the C1-5 alkyl, C3-7 cycloalkyl, and 4- 7 membered heterocycloalkyl of R k is each optionally substituted with 1 or 2 independently selected C1-5 alkyl groups.
  • X 2 is N or CR 2 ;
  • X 4 is N or CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is N or CR 7 ;
  • Y 1 is Ci-6 haloalkyl, wherein each halogen is F;
  • R 1 is selected from H, D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, halo, C1-5 alkyl, Ci-6 alkoxy, C2-5 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, CN, OR a , and SR a , wherein the C1-5 alkyl, C1-5 alkoxy, C 2 - 6 alkenyl, C 2 - 6 alkynyl, and C1-5 haloalkyl of R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each optionally substituted with 1, 2, 3, or 4 independently selected R h substituents;
  • R 8 is selected from H, D, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C 3 -10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the Ci-s alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, 6-10 membered aryl, C 3 -10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 9 substituents;
  • each R 9 is independently selected from halo, Ci-s alkyl, C1-5 haloalkyl, CN, OR k , and NR k R k ; wherein the C1-5 alkyl of R 9 is each optionally substituted with 1, 2, 3, or 4 independently selected R q substituents;
  • each R b is independently selected from halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, OR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c , NR c C(0)NR c R c , S(0)R c , S(0)NR c R c , S(0) 2 R c , and S(0) 2 NR c R c , wherein the C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, phenyl, C3-10 cyclo
  • each R c is independently selected from H, C1-5 alkyl, and C1-5 haloalkyl, wherein the Ci-6 alkyl and C1-5 haloalkyl of R c is each optionally substituted with 1, 2, 3, or 4
  • each R d is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, 4-7 membered heterocycloalkyl-Ci-6 alkyl-, OH, NO2, CN, halo, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, Ci-6 alkylsulfinyl, Ci-e alkylsulfonyl, carbamyl, C1-5 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, C1-5 alkoxycarbonyl, C1-5 alkylcarbonylamino, C1-5 alkylsulfonylamino, aminosulfonyl, Ci
  • each R e is independently selected from H, D, C1-5 alkyl, C1-5 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, Ci-6 haloalkoxy, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 6-10 membered aryl-Ci-6 alkyl-, C 3 -10 cycloalkyl- C1-6 alkyl-, 5-10 membered heteroaryl-Ci-6 alkyl-, and 4-10 membered heterocycloalkyl-Ci-6 alkyl;
  • each R k is independently selected from H, D, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocycloalkyl-Ci-4 alkyl-;
  • each R q is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, 4-7 membered heterocycloalkyl-Ci-6 alkyl-, OH, NO2, CN, halo, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, Ci-6 alkylsulfinyl, Ci-e alkylsulfonyl, carbamyl, C1-5 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, Ci-6 alkylsulfonylamino, aminosulfonyl, Ci- 6 al
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is CR 5 or N
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • Y 1 is a Ci-6 haloalkyl, wherein each halogen is selected from F, wherein the haloalkyl is optionally substituted with 1 or 2 independently selected Y 2 substituents;
  • R 1 is selected from H, D, halo, C1-5 alkyl, C1-5 haloalkyl, C5-10 membered heteroaryl, Cs-io membered heteroaryl-Ci -6 alkyl-, C(0)NR a R a , and C(0)OR a , wherein the C1-5 alkyl, Ci-s haloalkyl, C5-10 membered heteroaryl, C5-10 membered heteroaryl-Ci-6 alkyl- of R 1 are each optionally substituted with 1, 2, 3 or 4 independently selected R b substituents,
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently selected from H, D, halo, C1-5 alkyl and Ci-6 haloalkyl, wherein the C1-5 alkyl and C1-5 haloalkyl of R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each optionally substituted with 1, 2, 3 or 4 independently selected R h substituents;
  • Y 1 and R 8 form a 4-, 5-, 6-, or 7-membered cycloalkyl or heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R 9 substituents;
  • R 8 is selected from H, C1-5 alkyl, C3-10 cycloalkyl, C5-10 membered heteroaryl, C5-10 membered heteroaryl-Ci-6 alkyl-, wherein the C1-5 alkyl, C3-10 cycloalkyl, C5-10 membered heteroaryl, C5-10 membered heteroaryl-Ci-6 alkyl- of R 8 are each optionally substituted with 1, 2, 3 or 4 independently selected R 9 substituents.
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is CH or N
  • X 6 is N or CR 6 ;
  • X 7 is CH
  • Y 1 is CF 3 , CF 2 H, CFH 2 , CF 2 CF 3 , CFHY 2 or CF(Y 2 ) 2 ;
  • Y 2 is D or Ci-6 alkyl;
  • R 1 is selected from H, D, halo, Ci-s alkyl, C1-5 haloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-Ci -6 alkyl-, C(0)NR a R a , and C(0)OR a , wherein the C1-5 alkyl, Ci-s haloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-Ci-6 alkyl- is optionally substituted with 1, 2, 3 or 4 independently selected R b substituents;
  • Y 1 and R 8 form a 4-, 5-, 6-, or 7-membered cycloalkyl heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 independently selected R 9 substituents;
  • R 2 is H
  • R 3 is H
  • R 4 is H or halo
  • R 6 is H or halo
  • R 8 is selected from H, C1-5 alkyl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-Ci-6 alkyl-, wherein the C1-5 alkyl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-Ci-6 alkyl- of R 8 are each optionally substituted with 1, 2, 3 or 4 independently selected R 9 substituents.
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • R 2 is H, halo, CN, C1-5 alkyl, or C1-5 haloalkyl;
  • R 3 is H, halo, CN, C1-5 alkyl, or C1-5 haloalkyl;
  • R 4 is H, halo, CN, Ci -6 alkyl, or C « haloalkyl;
  • R 5 is H, halo, CN, C1-5 alkyl, or C1-5 haloalkyl;
  • R 6 is H, halo, CN, C1-5 alkyl, or C1-5 haloalkyl;
  • R 7 is H, halo, CN, C1-5 alkyl, or C1-5 haloalkyl;
  • R 1 is selected from H, D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6- 10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 4-, 5-, 6-, or 7-membered cycloalkyl group which is optionally substituted by 1 or 2 substituents independently selected from CI and F;
  • each R 9 is independently selected from halo, C1-5 alkyl, C1-5 haloalkyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, phenyl-Ci-3 alkyl-, C3-6 cycloalkyl-Ci-3 alkyl-, 5-6 membered heteroaryl-Ci-3 alkyl-, 4-6 membered heterocycloalkyl- C1-3 alkyl-, CN, OR k , C(0)R k , C(0)NR k R k , C(0)OR k , NR k R k , NR k C(0)R k , NR k C(0)OR k , NR k C(0)NR k R k , NR k S(0) 2 R k , NR k S(0) 2 NR k R k , S(0) 2 R k , and S(0) 2 NR k R k
  • each R a is independently selected from H, D, C1-5 alkyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered
  • heterocycloalkyl-Ci-6 alkyl- wherein the C1-5 alkyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, or 3 independently selected R b substituents;
  • each R b is independently selected from halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C 3 - 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, OR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c , NR c C(0)NR c R c , S(0)R c , S(0)NR c R c , S(0) 2 R c , and S(0) 2 NR c R c , wherein the C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, phenyl, C3-10 cycl
  • each R d is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, 4-7 membered heterocycloalkyl-Ci-6 alkyl-, OH, NO2, CN, halo, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alky lthio, Ci-6 alkylsulfinyl, Ci-e alkylsulfonyl, carbamyl, C1-5 alkyl
  • each R f is independently selected from OH, NO2, CN, halo, Ci-s alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci-6 alkylsulfinyl, Ci-6 alkylsulfonyl, carbamyl, Ci-s alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, Ci- 6 alkylsulfonylamino, amino
  • heterocycloalkyl phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocycloalkyl-Ci-4 alkyl-, wherein the C1-5 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-4 alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocycloalkyl-Ci-4 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4 independently selected R q substituents;
  • each R q is independently selected from D, halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-s haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered
  • heterocycloalkyl phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, 4-7 membered heterocycloalkyl-Ci-6 alkyl-, OH, NO2, CN, halo, Ci-6 alkoxy, C1-5 haloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, thio, C 1-6 alkylthio, Ci-6 alkylsulfinyl, Ci-e alkylsulfonyl, carbamyl, C1-5 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, Ci-6 alkoxycarbonyl, Ci-6 alkylcarbonylamino, C1-5 alkylsulfonylamino, aminosulfonyl, Ci- 6 al
  • each R n is independently selected from OH, NO2, CN, halo, C1-5 alkyl, C2-6 alkenyl, C2-5 alkynyl, Ci-6 haloalkyl, cyano-Ci-6 alkyl, HO-Ci-6 alkyl, Ci-6 alkoxy-Ci-6 alkyl, C3-7 cycloalkyl, Ci-6 alkoxy, Ci-e haloalkoxy, amino, Ci-6 alkylamino, di(C 1-6 alky l)amino, thio, C1-5 alkylthio, Ci- 6 alkylsulfinyl, Ci- 6 alkylsulfonyl, carbamyl, Ci-e alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, Ci- 6 alkylcarbonyl, Ci- 6 alkoxycarbonyl, Ci- 6 alkylcarbonylamino, Ci- 6 alkylsulfonylamin
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • R 2 is H
  • R 3 is H
  • R 4 is H, halo, or Ci-s alkyl
  • R 5 is H
  • R 6 is H or halo
  • R 7 is H
  • R 1 is selected from H, C1-5 alkyl, Ci-6 haloalkyl, phenyl, 5-6 membered heteroaryl, C(0)NR a R a , and C(0)OR a , wherein the C1-5 alkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R b substituents;
  • Y 1 is Ci-6 haloalkyl, wherein each halo is F;
  • R 8 is selected from H, C1-5 alkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C1-5 alkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 9 substituents; or
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 4-, 5-, or 6-membered cycloalkyl group which is optionally substituted by 1 or 2 F;
  • each R 9 is independently selected from halo, Ci-s alkyl, Ci-s haloalkyl, CN, OR k , and
  • Ci-s alkyl of R 9 is each optionally substituted with 1, 2, 3, or 4 independently selected R q substituents;
  • each R a is independently selected from H, Ci-s alkyl, C1-5 haloalkyl, phenyl-Ci-6 alkyl- , C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocy cloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C1-5 haloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered
  • heterocy cloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, or 3 independently selected R b substituents;
  • each R b is independently selected from halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, OR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c , NR c C(0)NR c R c , S(0)R c , S(0)NR c R c , S(0) 2 R c , and S(0) 2 NR c R c , wherein the C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, phenyl, C3-10 cycloal
  • each R c is independently selected from H, C1-5 alkyl, and C1-5 haloalkyl, wherein the Ci-s alkyl and C1-5 haloalkyl of R c is each optionally substituted with 1, 2, 3, or 4
  • each R d is independently selected from D, halo, C1-5 alkyl, C1-5 haloalkyl, OH, CN, Ci-6 alkoxy , C1-5 haloalkoxy , amino, C1-5 alky lamino, and di(Ci-6 alkyl)amino;
  • each R k is independently selected from H, C1-5 alkyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, alkyl-, C 3 -7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered
  • heterocy cloalkyl-Ci-4 alkyl- wherein the C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci- 4 alkyl-, C 3 -7 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocy cloalkyl-Ci-4 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected halo, C1-5 alkyl, C1-5 haloalkyl, OH, CN, C1-5 alkoxy, C 1-6 haloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, Ci-6 alkylsulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, C1-5 alkoxycarbonyl, Ci-e alkylcarbonylamino, C1-5 alkylsulfonylamino, aminosulfonyl, C1-5 alkylaminosulfonyl, and di(Ci- 6 alkyl)aminosulfonyl.
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • R 2 is H
  • R 3 is H
  • R 4 is H, halo, or Ci-s alkyl
  • R 5 is H
  • R 6 is H or halo
  • R 7 is H
  • R 1 is selected from H, Ci -6 alkyl, Ci-s haloalkyl, C(0)OR a , C(0)NR a R a , phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl; wherein said Ci- 6 alkyl, Ci-e haloalkyl, phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl are each optionally substituted by 1, 2, 3, or 4 independently selected R b substituents;
  • Y 1 is Ci-6 haloalkyl, wherein each halo is F;
  • R 8 is selected from H, C1-5 alkyl, C3-5 cycloalkyl, 5-6 membered heteroaryl, wherein the Ci-6 alkyl, C3-6 cycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R 9 substituents; or
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 4- 5-, or 6-membered cycloalkyl group which is optionally substituted by one F;
  • each R 9 is independently selected from Ci-s alkyl, OR k , and NR k R k ;
  • each R a is selected from H, C1-5 alkyl, and isoxazol-5-ylmethyl; wherein said isoxazol-5-ylmethyl is substituted by methyl and said C1-5 alkyl is optionally substituted by OH;
  • each R b is independently selected from halo, C1-5 alkyl, C3-6 cycloalkyl, OR c , and C(0)NR c R c , wherein the C1-5 alkyl and C3-6 cycloalkyl are each optionally substituted with 1 or 2 independently selected R d substituents;
  • each R c group is independently selected from H and C1-5 alkyl; each R d is independently selected from D, Ci-s alkyl and OH; and
  • each R k is independently selected from H, Ci-s alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl, wherein the Ci-s alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl of R k is each optionally substituted with 1 or 2 independently selected C1-5 alkyl groups.
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • R 2 is H
  • R 3 is H
  • R 4 is H, F, or methyl
  • R 5 is H
  • R 6 is H or F
  • R 7 is H
  • Y 1 is CF 3 , CHF 2 , CH 2 F, or CF 2 CF 3 ;
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl, wherein the phenyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, and 1,2,4-triazolyl are each optionally substituted by 1 or 2 independently selected R b substituents;
  • R 8 is selected from H, methyl, ethyl, 2-hydroxyethyl, 2-( -methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, and l-methyl-lH-tetrazol-5-yl;
  • each R a is independently selected from H, methyl, 2-hydroxy-2-methylpropyl, and (3- methylisoxazol-5-yl)methyl;
  • each R b is independently selected from fluoro, methyl, CD 3 , hydroxymethyl, methoxy, C(0)NH 2 , and cyclopropyl.
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is N or CR 5
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • R 2 is H
  • R 3 is H
  • R 4 is H, F, or methyl
  • R 5 is H
  • R 6 is H or F
  • R 7 is H
  • Y 1 is CF 3 , CHF 2 , CH 2 F, or CF 2 CF 3 ;
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, thiazol-5-yl, thiazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, oxazol-5-yl, pyrimidin-5-yl, pyridin-3- yl, pyridin-4-yl, isoxazol-5-yl, and 1,2,4-triazol-l-yl, wherein the phenyl, thiazol-5-yl, thiazol-2-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, oxazol-5-yl, pyrimidin-5-yl, pyridin-3- yl, pyridin-4-yl, isoxazol-5-yl, and 1,2,4-triazol-
  • R 8 is selected from H, methyl, ethyl, 2-hydroxyethyl, 2-( -methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, and l-methyl-lH-tetrazol-5-yl;
  • each R a is independently selected from H, methyl, 2-hydroxy-2-methylpropyl, and (3- methylisoxazol-5-yl)methyl;
  • each R b is independently selected from fluoro, methyl, CD 3 , hydroxymethyl, methoxy, C(0)NH 2 , and cyclopropyl.
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • R 2 is H
  • R 3 is H
  • R 4 is H, halo, or Ci-6 alkyl
  • R 5 is H;
  • R 6 is H or halo;
  • R 7 is H
  • R 1 is selected from H, Ci-s alkyl, Ci-6 haloalkyl, phenyl, 3-6 membered cycloalkyl, 5- 6 membered heteroaryl, 5-6 membered heterocycloalkyl, C(0)NR a R a , and C(0)OR a , wherein the Ci-6 alkyl, phenyl, 3-6 membered cycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R b substituents;
  • Y 1 is Ci-6 haloalkyl, wherein each halo is F;
  • R 8 is selected from H, Ci-s alkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the C 1 -5 alkyl, 6-10 membered aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered
  • heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 9 substituents; or
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 4-, 5-, or 6-membered cycloalkyl group which is optionally substituted by 1 or 2 F;
  • each R 9 is independently selected from halo, C1-5 alkyl, C1-5 haloalkyl, CN, OR k , and NR k R k ; wherein the C1-5 alkyl of R 9 is each optionally substituted with 1, 2, 3, or 4 independently selected R q substituents;
  • each R a is independently selected from H, C1-5 alkyl, C1-5 haloalkyl, phenyl-Ci-6 alkyl- , C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered heterocycloalkyl-Ci-6 alkyl-, wherein the C1-5 alkyl, C1-5 haloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalkyl-Ci-6 alkyl-, 5-6 membered heteroaryl-Ci-6 alkyl-, and 4-7 membered
  • heterocycloalkyl-Ci-6 alkyl- of R a is each optionally substituted with 1, 2, or 3 independently selected R b substituents;
  • each R b is independently selected from halo, C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, 6-10 membered aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, OR c , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c , NR c C(0)OR c , NR c C(0)NR c R c , S(0)R c , S(0)NR c R c , S(0) 2 R c , and S(0) 2 NR c R c , wherein the C1-5 alkyl, C2-5 alkenyl, C2-6 alkynyl, 6-10 membered aryl, C3
  • each R c is independently selected from H, C1-5 alkyl, and C1-5 haloalkyl, wherein the Ci-s alkyl and C1-5 haloalkyl of R c is each optionally substituted with 1, 2, 3, or 4
  • each R d is independently selected from D, halo, Ci-s alkyl, C1-5 haloalkyl, OH, CN, Ci-e alkoxy, Ci-ehaloalkoxy, amino, C 1-6 alky lamino, and di(Ci-6 alkyl)amino;
  • each R k is independently selected from H, C1-5 alkyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, alkyl-, C3-7 cycloalkyl-Ci-4 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered
  • heterocycloalkyl-Ci-4 alkyl- wherein the C1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-5 haloalkyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci- 4 alkyl-, C3-7 alkyl-, 5-6 membered heteroaryl-Ci-4 alkyl-, and 4-7 membered heterocycloalkyl-Ci-4 alkyl- of R k is each optionally substituted with 1, 2, 3, or 4
  • each R q is independently selected halo, C1-5 alkyl, C1-5 haloalkyl, OH, CN, C1-5 alkoxy, Ci-ehaloalkoxy, amino, C1-5 alkylamino, di(Ci-6 alkyl)amino, Ci-6 alkylsulfonyl, carbamyl, Ci-6 alkylcarbamyl, di(Ci-6 alkyl)carbamyl, carboxy, C1-5 alkylcarbonyl, C1-5 alkoxycarbonyl, Ci-e alkylcarbony lamino, C1-5 alky lsulfony lamino, aminosulfonyl, C1-5 alkylaminosulfonyl, and di(Ci- 6 alkyl)aminosulfonyl.
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • R 2 is H
  • R 3 is H
  • R 4 is H, halo, or Ci-s alkyl
  • R 5 is H
  • R 6 is H or halo
  • R 7 is H
  • R 1 is selected from H, Ci -6 alkyl, C ⁇ haloalkyl, C(0)OR a , C(0)NR a R a , phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4-triazolyl, and piperidinyl; wherein said C 1-5 alkyl, C1-5 haloalkyl, phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4-triazolyl, and piperidinyl are each optionally substituted by 1, 2, 3, or 4 independently selected R b substituents;
  • Y 1 is Ci-6 haloalkyl, wherein each halo is F; R is selected from H, Ci-s alkyl, C3-5 cycloalkyl, 5-6 membered heteroaryl, wherein the Ci-6 alkyl, C3-6 cycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R 9 substituents; or
  • Y 1 and R 8 together with the carbon atom to which they are attached, form a 4- 5-, or 6-membered cycloalkyl group which is optionally substituted by one F;
  • each R 9 is independently selected from Ci-s alkyl, OR k , and NR k R k ;
  • each R a is selected from H, C1-5 alkyl, and isoxazol-5-ylmethyl; wherein said isoxazol-5-ylmethyl is substituted by methyl and said C1-5 alkyl is optionally substituted by OH;
  • each R b is independently selected from halo, C1-5 alkyl, C3-6 cycloalkyl, OR c , and C(0)NR c R c , wherein the C1-5 alkyl and C3-6 cycloalkyl are each optionally substituted with 1 or 2 independently selected R d substituents;
  • each R c group is independently selected from H and C1-5 alkyl
  • each R d is independently selected from D, C1-5 alkyl and OH;
  • each R k is independently selected from H, C1-5 alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl, wherein the Ci-s alkyl, C3-7 cycloalkyl, and 4-7 membered heterocycloalkyl of R k is each optionally substituted with 1 or 2 independently selected C1-5 alkyl groups.
  • X 2 is N or CR 2 ;
  • X 4 is CR 4 ;
  • X 5 is N or CR 5 ;
  • X 6 is N or CR 6 ;
  • X 7 is CR 7 ;
  • R 2 is H
  • R 3 is H
  • R 4 is H, F, methyl, or CD 3 ;
  • R 5 is H
  • R 6 is H or F
  • R 7 is H
  • Y 1 is CF 3 , CHF 2 , CH 2 F, or CF 2 CF 3 ;
  • R 1 is selected from H, methyl, CF 3 , C(0)OR a , C(0)NR a R a , phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4-triazolyl, and piperindinyl, wherein the phenyl, cyclopropyl, thiazolyl, pyrazolyl, oxazolyl, pyrimidinyl, pyridinyl, isoxazolyl, 1,2,4-triazolyl, and piperidinyl are each optionally substituted by 1 or 2 independently selected R b substituents;
  • R 8 is selected from H, methyl, hydroxymethyl, ethyl, 2-hydroxyethyl, 2-(N- methylamino)ethyl, 2-(N- ⁇ tetrahydro-2H-pyran-4-yl ⁇ amino)ethyl, cyclopropyl, and 1-methyl- lH-tetrazol-5-yl;
  • each R a is independently selected from H, methyl, 2-hydroxy-2-methylpropyl, and (3- methylisoxazol-5-yl)methyl;
  • each R b is independently selected from fluoro, methyl, CD 3 , hydroxymethyl, methoxy, C(0)NH 2 , and cyclopropyl.
  • the compound of Formula (I) is a compound of Formula (II):
  • variables R 1 , R 2 , R 3 , X 4 , X 5 , X 6 , X 7 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula (III):
  • variables R 1 , R 3 , X 4 , X 5 , X 6 , X 7 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula (IV):
  • the compound of Formula (I) is a compound of Formula (V):
  • variables R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula (VI):
  • variables X 4 , X 5 , X 6 , X 7 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula (VII):
  • variables X 4 , X 5 , X 6 , X 7 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula
  • variables R 1 , X 4 , X 5 , X 6 , X 7 , and R 8 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula
  • variables R 1 , X 4 , X 5 , X 6 , X 7 , and R 8 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula (IX):
  • variables R 1 , X 4 , X 5 , X 6 , X 7 , and R 8 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula
  • variables R 1 , X 4 , X 5 , X 6 , X 7 , and R 8 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula (X):
  • variables R 1 , R 4 , R 6 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula (XI):
  • variables R 1 , R 4 , R 6 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula (XII):
  • variables R 1 , R 4 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • the compound of Formula (I) is a compound of Formula
  • variables R 1 , X 4 , X 6 , R 8 , and Y 1 are defined according to the definitions provided herein for compounds of Formula (I).
  • each divalent linking substituent include both the forward and backward forms of the linking substituent.
  • -NR(CR'R") n - includes both -NR(CR'R") n - and -(CR'R") n NR-.
  • the Markush variables listed for that group are understood to be linking groups.
  • n-membered where n is an integer typically describes the number of ring- forming atoms in a moiety where the number of ring-forming atoms is n.
  • piperidinyl is an example of a 6-membered heterocycloalkyl ring
  • pyrazolyl is an example of a 5-membered heteroaryl ring
  • pyridyl is an example of a 6-membered heteroaryl ring
  • 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
  • the phrase "optionally substituted” means unsubstituted or substituted.
  • the substituents are independently selected, and substitution may be at any chemically accessible position.
  • substituted means that a hydrogen atom is removed and replaced by a substituent.
  • a single divalent substituent, e.g., oxo, can replace two hydrogen atoms. It is to be understood that substitution at a given atom is limited by valency.
  • C n - m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include Ci-4, Ci-s, and the like.
  • C n - m alkyl refers to a saturated hydrocarbon group that may be straight-chain or branched, having n to m carbons.
  • alkyl moieties include, but are not limited to, chemical groups such as methyl (Me), ethyl (Et), ra-propyl ( «-Pr), isopropyl (iPr), ra-butyl, /er/-butyl, isobutyl, sec-butyl; higher homologs such as 2-methyl-l -butyl, ra-pentyl, 3-pentyl, ra-hexyl, 1,2,2- trimethylpropyl, and the like.
  • the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.
  • C n - m alkenyl refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons.
  • Example alkenyl groups include, but are not limited to, ethenyl, ra-propenyl, isopropenyl, ra-butenyl, seobutenyl, and the like.
  • the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
  • C n - m alkynyl refers to an alkyl group having one or more triple carbon-carbon bonds and having n to m carbons.
  • Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like.
  • the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
  • C n - m alkoxy refers to a group of formula -O-alkyl, wherein the alkyl group has n to m carbons.
  • Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n- propoxy and isopropoxy), butoxy (e.g., ra-butoxy and /ert-butoxy), and the like.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • amino refers to a group of formula -NH 2 .
  • aryl employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or poly cyclic (e.g., having 2, 3 or 4 fused rings).
  • C n -maryi refers to an aryl group having from n to m ring carbon atoms.
  • Aryl groups include, e.g., phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like.
  • the aryl group has from 5 to 10 carbon atoms.
  • the aryl group is phenyl or naphthyl.
  • the aryl group is phenyl.
  • halo refers to F, CI, Br, or I. In some embodiments, a halo is F, CI, or Br. In some embodiments, a halo is F or CI. In some embodiments, a halo is CI.
  • C n - m haloalkoxy refers to a group of formula -O-haloalkyl having n to m carbon atoms.
  • Example haloalkoxy groups include OCF 3 and OCHF 2 .
  • the haloalkoxy group is fluorinated only.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • C n - m haloalkyl refers to an alkyl group having from one halogen atom to 2s+l halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms.
  • the haloalkyl group is fluorinated only.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Example haloalkyl groups include CF 3 , C2F5, CHF 2 , CH 2 F, CCI3, CHCI2, C2CI5 and the like.
  • C n - m alkylamino refers to a group of formula -NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • C n -malkoxycarbonyl refers to a group of formula -C(0)0- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • C n -malkylcarbonyl refers to a group of formula -C(O)- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • C n - m alkylcarbonylamino refers to a group of
  • the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • C n - m alkylsulfonylamino refers to a group of
  • formula -NHS(0) 2 -alkyl wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • aminosulfonyl refers to a group of formula -S(0)2NH 2 .
  • C n -malkylaminosulfonyl refers to a group of
  • di(C n - m alkyl)aminosulfonyl refers to a group of formula -S(0)2N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • aminosulfonylamino refers to a group of formula - NHS(0) 2 NH 2 .
  • Cn- m alkylaminosulfonylamino refers to a group of formula -NHS(0) 2 NH(alkyl), wherein the alkyl group has n to m carbon atoms.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • di(Cn- m alkyl)aminosulfonylamino refers to a group of formula -NHS(0)2N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • aminocarbonylamino employed alone or in combination with other terms, refers to a group of formula -NHC(0)NH 2 .
  • C n - m alkylaminocarbonylamino refers to a group of formula -NHC(0)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • di(C n - m alkyl)aminocarbonylamino refers to a group of formula -NHC(0)N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Cn-malkylcarbamyl refers to a group of formula -C(O)-
  • the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • thio refers to a group of formula -SH.
  • Cn- m alkylthio refers to a group of formula -S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • C n -malkylsulfinyl refers to a group of formula -S(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • C n -malkylsulfonyl refers to a group of formula -S(0)2- alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • carbonyl employed alone or in combination with other terms, refers to a -C(O)- group.
  • cyano-Ci-3 alkyl refers to a group of formula -(Ci-s alkylene)-CN.
  • HO-Ci-6 alkyl refers to a group of formula -(Ci-s alkylene)-
  • HO-C1-3 alkyl refers to a group of formula -(C1-3 alkylene)-
  • Ci-6 alkoxy-Ci-6 alkyl refers to a group of formula -(C1-5 alkylene)-0(Ci- 6 alkyl).
  • C1-3 alkoxy-Ci-3 alkyl refers to a group of formula -(C1-3 alkylene)-0(Ci-3 alkyl).
  • carboxy refers to a group of formula - C(0)OH.
  • di(C n -m-alkyl)amino refers to a group of formula - N(alkyl) 2 , wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • di(C n -m-alkyl)carbamyl refers to a group of formula - C(0)N(alkyl) 2 , wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • cycloalkyl refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and/or alkenyl groups. Cycloalkyl groups can include mono- or polycyclic
  • cycloalkyl groups e.g., having 2 fused rings
  • spirocycles e.g., having bridged rings
  • bridged rings e.g. , a bridged bicycloalkyl group
  • Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O) or C(S)).
  • cycloalkyl moieties that have one or more aromatic rings fused (i.e. , having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of cyclopentane, cyclohexane, and the like.
  • a cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
  • Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (C3-10) .
  • the cycloalkyl is a C3-10 monocyclic or bicyclic cyclocalkyl.
  • the cycloalkyl is a C3-10 monocyclic or bicyclic cycloalkyl which is optionally substituted by CH 2 F, CHF 2 , CF 3 , and CF 2 CF 3 .
  • the cycloalkyl is a C3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4-10 spirocycle or bridged cycloalkyl.
  • Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cubane, adamantane, bicyclo[l. l .
  • cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • heteroaryl refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from N, O, S or B, wherein any ring forming N is optionally an N-oxide group.
  • the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from N, O, S and B.
  • any ring-forming N in a heteroaryl moiety can be an N-oxide.
  • the heteroaryl is a 5-10 membered monocyclic or bicyclic heteroaryl having 1, 2, 3 or 4 heteroatom ring members independently selected from N, O, S and B.
  • the heteroaryl is a 5-6 monocyclic heteroaryl having 1 or 2 heteroatom ring members independently selected from N, O, S and B. In some embodiments, the heteroaryl is a 5-6 monocyclic heteroaryl ring having 1 or 2 heteroatom ring members independently selected from N, O or S. In some embodiments, the heteroaryl group has 1 to 4 ring-forming heteroatoms, 1 to 3 ring-forming heteroatoms, 1 to 2 ring-forming heteroatoms or 1 ring- forming heteroatom. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different.
  • Example heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, imidazole, furan, thiophene, triazole, tetrazole, thiadiazole, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[l, 2- b]thiazole, purine, triazine , thieno[3,2-£]pyridine, imidazo[l,2-a]pyridine, 1,5-naphthyridine, li/-pyrazolo[4,3-£]pyridine and the like.
  • a five-membered heteroaryl ring is a heteroaryl group having five ring-forming atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, S and B.
  • Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3- thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- triazolyl, 1,3,4-thiadiazolyl, 1,3,4-oxadiazolyl and l,2-dihydro-l,2-azaborine.
  • a six-membered heteroaryl ring is a heteroaryl group having six ring-forming atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, S and B.
  • Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
  • heterocycloalkyl refers to monocyclic or polycyclic heterocycles having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more of the ring-forming carbon atoms of the heterocycloalkyl is replaced by a heteroatom selected from N, O, S and B, and wherein the ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group can be optionally substituted by one or more oxo or sulfido (e.g., C(O), S(O), C(S), or S(0)2, etc.).
  • oxo or sulfido e.g., C(O), S(O), C(S), or S(0)2, etc.
  • Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having 2 fused rings) systems. Included in heterocycloalkyl are monocyclic and polycyclic 3-10, 4-10, 3-7, 4-7, and 5-6 membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles and bridged rings (e.g., a 5-10 membered bridged biheterocycloalkyl ring having one or more of the ring-forming carbon atoms replaced by a heteroatom independently selected from N, O, S and B). The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments,
  • the heterocycloalkyl group contains 0 to 2 double bonds.
  • heterocycloalkyl moieties that have one or more aromatic rings fused (i.e. , having a bond in common with) to the non-aromatic heterocyclic ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc.
  • a heterocycloalkyl group containing a fused aromatic ring can be attached through any ring- forming atom including a ring-forming atom of the fused aromatic ring.
  • the heterocycloalkyl group contains 3 to 10 ring-forming atoms, 4 to 10 ring- forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms. In some
  • the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms or 1 heteroatom.
  • the heterocycloalkyl is a monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, S and B and having one or more oxidized ring members.
  • Example heterocycloalkyl groups include pyrrolidin-2-one, l,3-isoxazolidin-2-one, pyranyl, tetrahydropyran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, 1,2,3,4- tetrahydroisoquinoline, azabicyclo[3. l.OJhexanyl, diazabicyclo[3. l.OJhexanyl,
  • C 0 - P cycloalkyl-Cn-malkyl- refers to a group of formula cycloalkyl- alkylene-, wherein the cycloalkyl has o to p carbon atoms and the alkylene linking group has n to m carbon atoms.
  • C 0 - p aryl-C n - m alkyl- refers to a group of formula aryl-alkylene-, wherein the aryl has o to p carbon atoms and the alkylene linking group has n to m carbon atoms.
  • heteroaryl-C n - m alkyl- refers to a group of formula heteroaryl- alkylene-, wherein alkylene linking group has n to m carbon atoms.
  • heterocycloalkyl-C n - m alkyl- refers to a group of formula heterocycloalkyl-alkylene-, wherein alkylene linking group has n to m carbon atoms.
  • the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas a pyridin-3-yl ring is attached at the 3-position.
  • the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms.
  • the compound has the (R) -configuration.
  • the compound has the (Si-configuration.
  • the Formulas (e.g. , Formula (I), (II), etc.) provided herein include stereoisomers of the compounds.
  • Formulas (I)-(XIII) herein include stereoisomers of the compounds.
  • the carbon atom to which R 8 and Y 1 are attached is in the (R)-configuration.
  • the carbon atom to which R 8 and Y 1 are attached is in the (S)- configuration.
  • An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid.
  • Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as ⁇ - camphorsulfonic acid.
  • resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.
  • Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
  • Suitable elution solvent composition can be determined by one skilled in the art.
  • Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
  • Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, 2-hydroxypyridine and 2-pyridone, and 1H- and 2H- pyrazole.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated.
  • preparation of compounds can involve the addition of acids or bases to affect, for example, catalysis of a desired reaction or formation of salt forms such as acid addition salts.
  • Example acids can be inorganic or organic acids and include, but are not limited to, strong and weak acids.
  • Some example acids include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, ⁇ -toluenesulfonic acid, 4-nitrobenzoic acid, methanesulfonic acid, benzenesulfonic acid, trifluoroacetic acid, and nitric acid.
  • Some weak acids include, but are not limited to acetic acid, propionic acid, butanoic acid, benzoic acid, tartaric acid, pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, and decanoic acid.
  • Example bases include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, and sodium bicarbonate.
  • Some example strong bases include, but are not limited to, hydroxide, alkoxides, metal amides, metal hydrides, metal dialkylamides and arylamines, wherein; alkoxides include lithium, sodium and potassium salts of methyl, ethyl and t-butyl oxides; metal amides include sodium amide, potassium amide and lithium amide; metal hydrides include sodium hydride, potassium hydride and lithium hydride; and metal dialkylamides include lithium, sodium, and potassium salts of methyl, ethyl, n-propyl, zso-propyl, n-butyl, /ert-butyl, trimethylsilyl and cyclohexyl substituted amides.
  • the compounds provided herein, or salts thereof are substantially isolated.
  • substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
  • Partial separation can include, for example, a composition enriched in the compounds provided herein.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the present application also includes pharmaceutically acceptable salts of the compounds described herein.
  • the present disclosure also includes pharmaceutically acceptable salts of the compounds described herein.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two;
  • non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso- propanol, or butanol) or acetonitrile (ACN) are preferred.
  • alcohols e.g., methanol, ethanol, iso- propanol, or butanol
  • ACN acetonitrile
  • the compounds provided herein can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
  • halogen e.g., CI, Br, or I
  • pseudohalogen e.g., OTf or OMs
  • Bicycle 1-1 can be coupled with 1-2, where M 1 is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal, such as Sn(Bu)3 or Zn, under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) or [ ⁇ , ⁇ - bis(diphenylphosphino)ferrocene]dichloropalladium (II), complex with dichloromethane and a base (e.g., a carbonate base)) or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as
  • the Y 9 group can be converted to an appropriate substituted metal 1-4 (e.g., M 2 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu)3, or Zn) and then coupled to 1-5 where W is halogen (e.g., CI, Br, or I) or pseudohalogen (e.g., OTf or OMs) under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as
  • halogen e.g., F or Br or H
  • the W halo (e.g., CI, Br, or I) or pseudohalo group (e.g., OTf or OMs) of alcohol 2-3 can be converted to an appropriate substituted metal 2-4 (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu) 3 , or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl)]palladium or
  • aldehyde 3-1 can be reacted with a nucleophile (e.g., a Grignard reagent or alkyllithium reagent) to afford secondary alcohol 3-2.
  • the secondary alcohol 3-2 can be oxidized to ketone 3-3.
  • a nucleophile e.g., a Grignard reagent or alkyllithium reagent
  • the secondary alcohol 3-2 can be oxidized to ketone 3-3.
  • the Y 2 halo (e.g., CI, Br, or I) or pseudohalo group (e.g., OTf or OMs) of alcohol 3-5 can be converted to an appropriate substituted metal 3-6 (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu) 3 , or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl)]palladium or
  • the secondary alcohol 4-3 can be oxidized to ketone 4-4.
  • Ketone 4-4 can be reacted with a nucleophile (e.g., a Grignard reagent or alkyllithium reagent) to afford tertiary alcohol 4-5.
  • a nucleophile e.g., a Grignard reagent or alkyllithium reagent
  • the W halo (e.g., CI, Br, or I) or pseudohalo group (e.g., OTf or OMs) of alcohol 4-5 can be converted to an appropriate substituted metal 4-6 (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu) 3 , or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl)]palladium or
  • W halo e.g., CI, Br, or I
  • pseudohalo group e.g., OTf or OMs
  • R 8 is H (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as
  • the W halo (e.g., CI, Br, or I) or pseudohalo group (e.g., OTf or OMs) of alcohol 5-5 can be converted to an appropriate substituted metal 5-6 (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu) 3 , or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro [bis(tripheny lphosphorany l)]palladium or
  • the amino group of 6-3 can be optionally protected with a suitable protecting group P, (e.g., acetyl), under standard conditions (e.g., in the presence of acetyl chloride or acetic anhydride, a base (e.g., triethylamine), and optionally a catalyst (e.g., 4- dimethylaminopyridine)) to give the protected amine 6-4.
  • a suitable protecting group P e.g., acetyl
  • a base e.g., triethylamine
  • a catalyst e.g., 4- dimethylaminopyridine
  • Compound 6-4 can be halogenated with suitable reagents, such as N-chlorosuccinimide, N-bromosuccinimide, or N- iodosuccinimide, to give halide 6-5 where Y 9 is a halo group (e.g., CI, Br, or I).
  • Halide 6-5 can be selectively coupled with 1-2, where M 1 is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal such as Sn(Bu)3 or Zn, under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as
  • tetrakis(triphenylphosphine)palladium(0) and a base e.g., a carbonate base
  • a base e.g., a carbonate base
  • standard Stille conditions e.g., in the presence of a palladium(O) catalyst, such as
  • compound 6-6 can be coupled with 6-7, where M 4 is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal, such as Sn(Bu)3 or Zn, under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as
  • halide 6-5 can be selectively coupled with 6-7, where M 4 is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal such as Sn(Bu) 3 or Zn, under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with
  • M 4 is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal such as Sn(Bu) 3 or Zn
  • a palladium(O) catalyst such as tetrakis(triphenylphosphine)palladium(0)
  • hetereoaromatic amine 7-1 where Y 4 and Y 6 are halo groups
  • alpha-halo carbonyl derivatives 6-2 where Y 5 is a halogen (e.g., CI or Br)
  • Y 5 is a halogen (e.g., CI or Br)
  • suitable reagents such as N-chlorosuccinimide, N- bromosuccinimide, or N-iodosuccinimide can give halide 7-3 where Y 9 is a halo group (e.g., CI, Br, or I).
  • Nucleophilic aromatic substitution of the halide of 7-3 with amine 7-4 can provide halide 7-5.
  • Halide 7-5 can be selectively coupled with 1-2, where M 1 is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal such as Sn(Bu)3 or Zn, under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a carbonate base)) or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as
  • compound 7-6 can be coupled with 7-7, where M 4 is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal such as Sn(Bu)3 or Zn, under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as
  • hetereoaromatic amine 8-1 where Y 6 is a halogen group
  • alpha- halo carbonyl derivatives 6-2 where Y 5 is a halogen (e.g., CI or Br)
  • Y 5 is a halogen (e.g., CI or Br)
  • suitable reagents such as N-chlorosuccinimide, N- bromosuccinimide, or N-iodosuccinimide
  • halide 8-3 where Y 9 is a halo group (e.g., CI, Br, or I).
  • halide 8-3 with amine 8-4 (e.g., NH 3 or p-methoxybenzylamine) can provide halide 8-5 with an optionally protected amine.
  • Halide 8- 5 can be further reacted according to Scheme I to afford the resulting compounds of Formula (I).
  • Scheme VIII Nucleophilic aromatic substitution of the halide 8-3 with amine 8-4 (e.g., NH 3 or p-methoxybenzylamine) can provide halide 8-5 with an optionally protected amine.
  • Halide 8- 5 can be further reacted according to Scheme I to afford the resulting compounds of Formula (I).
  • R 12 can be alkyl
  • 9-1 e.g., R 12 can be alkyl
  • an NH 2 -transfer agent such as chloramine, O- (diphenylphosphinyl)hydroxylamine, or 0-(4-nitrobenzoyl)hydroxylamine and a base such as sodium hydride, lithium hexamethyldisilazane, or potassium tert-butoxide
  • condensation with an alkyl chloroformate CICO2R 13 where R 13 can be an alkyl group
  • standard conditions e.g., treatment with an appropriate base such as pyridine or sodium bicarbonate
  • Cyclization of 9-2 in the presence of a suitable ammonia source can provide bicycle 9-3.
  • the bicycle 9-3 can be halogenated with suitable reagents, such as N-chlorosuccinimide, N-bromosuccinimide, or N- iodosuccinimide, to give a halide 9-4 where Y 9 is a halo group (e.g., CI, Br, or I).
  • Dehydrative halogenation e.g., by treating with a reagent such as POCI3 or POBr 3
  • Nucleophihc aromatic substitution of the halide of 9-5 with amine 9-6 e.g., NH 3 or p-methoxybenzylamine
  • intermdediate 9-7 with an optionally protected amine.
  • Intermediate 9-7 can be selectively coupled with 1-2, where M 1 is a boronic acid, boronate ester, potassium trifluoroborate, or an appropriately substituted metal such as Sn(Bu)3 or Zn, under standard Suzuki conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) and a base (e.g., a carbonate base)) or standard Stille conditions (e.g., in the presence of a palladium(O) catalyst, such as tetrakis(triphenylphosphine)palladium(0)) or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) or [1,1'- bis(diphenylphosphino)ferrocene] dichloropalladium (II)), to give compound 9-8.
  • ketone 11-1 can be converted to alkene 11-3 under standard olefination conditions such as reactions with ylides 11-2 (e.g.,
  • Alkene 11-3 can be converted to the fluorinated alcohol 11- 4 with a reagent such as Selectfluor ® and water.
  • the W halo (e.g., CI, Br, or I) or pseudohalo group (e.g., OTf or OMs) of alcohol 11-4 can be converted to an appropriate substituted metal 11-5 (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu)3, or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro [bis(tripheny lphosphorany l)]palladium or
  • heteroaromatic amine 12-2 halogenation of heteroaromatic amine 12-2 with suitable reagents, such as N-chlorosuccinimide, N- bromosuccinimide, Br 2 , or N-iodosuccinimide, optionally in the presence of a base, such sodium bicarbonate or sodium carbonate, can give compound 12-3, where Y 6 is a halo group (e.g., CI, Br, or I).
  • Nucleophilic aromatic substitution of compound 12-3 with amine 12-4 e.g., NH 3 or p-methoxybenzylamine
  • Compounds provided herein can be synthesized from intermediates 12-3 and 12-5 using the methods described in Scheme VII and Scheme VI, respectively.
  • Dihydroxylation of alkene 13-2 using reagents suitable for dihydroxylation can afford diol-containing intermediate 13-3.
  • Diol 13-3 can be converted to epoxide 13-4 using tosyl chloride and a suitable base (e.g., triethylamine).
  • Epoxide 13-4 can be treated with a variety of amines (e.g., R m and R n can be R b or R c ) to give amino alcohols 13-5.
  • the W halo (e.g., CI, Br, or I) or pseudohalo group (e.g., OTf or OMs) of alcohol 13-5 can be converted to an appropriate substituted metal 13-6 (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu) 3 , or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl)] palladium or
  • Diol-containing compounds of Formula (I) can be prepared as shown in Scheme 13b.
  • boron reagent 13b-l e.g., R p can be alkyl
  • haloalkene 13b-2 where Y 5 is a halogen and Y 1 can be CF 3
  • alkene 13b-3 e.g., wherein R 10 and R n can each be R 9
  • Dihydroxylation with an appropriate oxidizing agent e.g., osmium tetroxide and a re-oxidant such as A f -methylmorpholine- -oxide, or AD-mix a or AD-mix ⁇
  • diol 13b-4 e.g., osmium tetroxide and a re-oxidant such as A f -methylmorpholine- -oxide, or AD-mix a or AD-mix ⁇
  • the W halo (e.g., CI, Br, or I) or pseudohalo group (e.g., OTf or OMs) of diol 13b-4 can be converted to an appropriate substituted metal 13b-5 (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu)3, or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as
  • nitrile 14-1 can be converted to ketone 14-2 (e.g., wherein R b can be R 9 ) with addition of a Grignard reagent.
  • Ketone 14-2 can be brominated (e.g., Br 2 ) to give bromoketone 14-3.
  • the bromine of 14-3 can be displaced with a variety of amines to give 14- 4.
  • Y 1 e.g., CF 3 or CF 2 H
  • Z 1 is a halogen (e.g., F or Br or H) under standard conditions (e.g., in the presence of TBAF or PPh 3 and DMPU).
  • the W halo (e.g., CI, Br, or I) or pseudohalo group (e.g., OTf or OMs) of alcohol 14-5 can be converted to an appropriate substituted metal 14-6 (e.g., M 1 is B(OH) 2 , Bpin, BF 3 K, Sn(Bu) 3 , or Zn) under standard conditions (e.g., in the presence of a diboron reagent such as bis(pinacolato)diboron, a palladium catalyst, such as dichloro[bis(triphenylphosphoranyl)]palladium or

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2018/056311 2017-10-18 2018-10-17 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA Ceased WO2019079469A1 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
EP21196484.6A EP4006034A1 (en) 2017-10-18 2018-10-17 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
RS20211581A RS62818B1 (sr) 2017-10-18 2018-10-17 Kondenzovani derivati imidazola zamenjeni tercijarnim hidroksi grupama kao inhibitorima pi3k-gamma
PE2020000403A PE20210169A1 (es) 2017-10-18 2018-10-17 Derivados de imidazol condensados sustituidos por grupos de hidroxia terciaria como inhibidores de pi3k-y gamma
KR1020247033485A KR20240152947A (ko) 2017-10-18 2018-10-17 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
SG11202003428VA SG11202003428VA (en) 2017-10-18 2018-10-17 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CN201880081276.3A CN111542526B (zh) 2017-10-18 2018-10-17 作为PI3K-γ抑制剂的由叔羟基取代的缩合咪唑衍生物
CA3084589A CA3084589A1 (en) 2017-10-18 2018-10-17 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
IL295978A IL295978B2 (en) 2017-10-18 2018-10-17 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
EA202090969A EA202090969A1 (ru) 2018-09-05 2018-10-17 Третичные спирты в качестве ингибиторов pi3k-
HRP20211827TT HRP20211827T1 (hr) 2017-10-18 2018-10-17 Kondenzirani derivati imidazola supstituirani s tercijarnim hidroksi skupinama kao inhibitori pi3k-gama
CR20210442A CR20210442A (es) 2017-10-18 2018-10-17 ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214)
SI201830506T SI3697789T1 (sl) 2017-10-18 2018-10-17 Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
MA50398A MA50398B1 (fr) 2017-10-18 2018-10-17 Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
CN202311732701.XA CN118063470A (zh) 2017-10-18 2018-10-17 作为PI3K-γ抑制剂的由叔羟基取代的缩合咪唑衍生物
SM20210656T SMT202100656T1 (it) 2017-10-18 2018-10-17 Derivati di imidazolo condensati sostituiti con gruppi ossidrile terziari come inibitori di pi3k-gamma
IL295978A IL295978B1 (en) 2017-10-18 2018-10-17 Concentrated imidazole derivatives substituted by tertiary hydroxy groups as P13K-gamma inhibitors
PL18797408T PL3697789T3 (pl) 2017-10-18 2018-10-17 Skondensowane pochodne imidazolowe podstawione przez trzeciorzędowe grupy hydroksylowe, jako inhibitory pi3k-gamma
UAA202002916A UA128085C2 (uk) 2017-10-18 2018-10-17 ТРЕТИННІ СПИРТИ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font>
EP18797408.4A EP3697789B1 (en) 2017-10-18 2018-10-17 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
MX2020003862A MX2020003862A (es) 2017-10-18 2018-10-17 Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
ES18797408T ES2902390T3 (es) 2017-10-18 2018-10-17 Derivados de imidazol condensados sustituidos por grupos hidroxi terciarios como inhibidores de PI3K-gamma
AU2018350980A AU2018350980C1 (en) 2017-10-18 2018-10-17 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
LTEPPCT/US2018/056311T LT3697789T (lt) 2017-10-18 2018-10-17 Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
JP2020521911A JP7244504B2 (ja) 2017-10-18 2018-10-17 ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体
BR112020007593-0A BR112020007593A2 (pt) 2017-10-18 2018-10-17 derivados de imidazol condensados substituídos por grupos hidróxi terciários como inibidores de pi3k-gama
CR20200214A CR20200214A (es) 2017-10-18 2018-10-17 ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
MDE20200857T MD3697789T2 (ro) 2017-10-18 2018-10-17 Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA
KR1020207014142A KR102717072B1 (ko) 2017-10-18 2018-10-17 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
IL273983A IL273983B2 (en) 2017-10-18 2020-04-16 Concentrated imidazole derivatives substituted by tertiary hydroxy groups as p13k-gamma inhibitors
PH12020550442A PH12020550442A1 (en) 2017-10-18 2020-04-17 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
JOJO/P/2020/0086A JOP20200086B1 (ar) 2017-10-18 2020-04-30 مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما
CY20211101062T CY1124814T1 (el) 2017-10-18 2021-12-03 Συμπυκνωμενα παραγωγα ιμιδαζολιου υποκατεστημενα με τριτοταγεις υδροξυ ομαδες ως αναστολεις ρi3κ-γαμμα
JP2023036727A JP7541594B2 (ja) 2017-10-18 2023-03-09 ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体
AU2023203088A AU2023203088B2 (en) 2017-10-18 2023-05-17 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
AU2024287193A AU2024287193A1 (en) 2017-10-18 2024-12-23 Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762574057P 2017-10-18 2017-10-18
US62/574,057 2017-10-18
US201762608897P 2017-12-21 2017-12-21
US62/608,897 2017-12-21
US201862727316P 2018-09-05 2018-09-05
US62/727,316 2018-09-05

Publications (1)

Publication Number Publication Date
WO2019079469A1 true WO2019079469A1 (en) 2019-04-25

Family

ID=64110207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/056311 Ceased WO2019079469A1 (en) 2017-10-18 2018-10-17 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA

Country Status (35)

Country Link
US (4) US10738057B2 (https=)
EP (2) EP4006034A1 (https=)
JP (2) JP7244504B2 (https=)
KR (2) KR102717072B1 (https=)
CN (2) CN111542526B (https=)
AU (3) AU2018350980C1 (https=)
BR (1) BR112020007593A2 (https=)
CA (1) CA3084589A1 (https=)
CL (1) CL2020001047A1 (https=)
CR (2) CR20210442A (https=)
CY (1) CY1124814T1 (https=)
EC (1) ECSP20024651A (https=)
ES (1) ES2902390T3 (https=)
GE (4) GEAP202416013A (https=)
HR (1) HRP20211827T1 (https=)
HU (1) HUE056615T2 (https=)
IL (3) IL295978B2 (https=)
JO (1) JOP20200086B1 (https=)
LT (1) LT3697789T (https=)
MA (1) MA50398B1 (https=)
MD (1) MD3697789T2 (https=)
MX (1) MX2020003862A (https=)
PE (1) PE20210169A1 (https=)
PH (1) PH12020550442A1 (https=)
PL (1) PL3697789T3 (https=)
PT (1) PT3697789T (https=)
RS (1) RS62818B1 (https=)
SA (1) SA520411783B1 (https=)
SG (1) SG11202003428VA (https=)
SI (1) SI3697789T1 (https=)
SM (1) SMT202100656T1 (https=)
TW (2) TWI834560B (https=)
UA (1) UA128085C2 (https=)
WO (1) WO2019079469A1 (https=)
ZA (1) ZA202201220B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021165246A (ja) * 2020-04-08 2021-10-14 国立大学法人 名古屋工業大学 ペンタフルオロエチル基含有アルコール類の製造方法、有機半導体材料および酵素活性阻害剤の製造中間体化合物
CN113677683A (zh) * 2018-09-05 2021-11-19 因赛特公司 磷酸肌醇3激酶(pi3k)抑制剂的结晶形式
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
WO2025031468A1 (zh) 2023-08-09 2025-02-13 江苏恒瑞医药股份有限公司 杂芳基化合物、其制备方法及其在医药上的应用
US12365668B2 (en) 2018-03-08 2025-07-22 Incyte Corporation Aminopyrazine diol compounds as PI3K-y inhibitors
US12421197B2 (en) 2018-07-02 2025-09-23 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
CN114206332B (zh) 2019-06-04 2024-08-23 艾库斯生物科学有限公司 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物
CN115286521B (zh) * 2022-07-11 2023-11-03 上海医药集团(本溪)北方药业有限公司 一种盐酸左沙丁胺醇的合成方法
CN120677157A (zh) * 2024-01-18 2025-09-19 海创药业股份有限公司 一种制备雄激素受体靶向降解化合物及其盐的方法

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
WO2000053595A1 (en) 1999-03-06 2000-09-14 Astrazeneca Ab Pyrimidine compounds
WO2001014402A1 (en) 1999-08-19 2001-03-01 Isis Pharmaceuticals, Inc. Antisense modulation of focal adhesion kinase expression
WO2001064655A1 (en) 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003099771A2 (en) 2002-05-29 2003-12-04 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2004046120A2 (en) 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases
WO2004056786A2 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivates for the treatment of abnormal cell growth
WO2004080980A1 (en) 2003-03-14 2004-09-23 Novartis Ag 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US20050009832A1 (en) * 2003-02-20 2005-01-13 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2005028444A1 (en) 2003-09-24 2005-03-31 Novartis Ag 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
WO2006056399A2 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
WO2009064835A1 (en) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009114512A1 (en) 2008-03-11 2009-09-17 Incyte Corporation Azetidine and cyclobutane derivatives as jak inhibitors
WO2013104610A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
WO2016064957A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
WO2016166239A1 (en) * 2015-04-16 2016-10-20 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
WO2016183094A1 (en) 2015-05-12 2016-11-17 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP1599474B1 (en) 2003-03-04 2013-04-24 California Institute Of Technology Heterocyclic oligomeric compounds for DNA recognition
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
UA83509C2 (en) * 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
US20080039450A1 (en) 2006-06-22 2008-02-14 Jensen Annika J Compounds
US20090131481A1 (en) 2007-03-27 2009-05-21 Paratek Pharmaceuticals, Inc. Transcription Factor Modulating Compounds and Methods of Use Thereof
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
US20110052562A1 (en) 2007-12-19 2011-03-03 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
AU2009232276B2 (en) 2008-01-15 2013-10-24 Kineta Four Llc Antiviral drugs for treatment of arenavirus infection
ATE555116T1 (de) 2008-02-26 2012-05-15 Merck Sharp & Dohme Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
WO2010051245A1 (en) 2008-11-03 2010-05-06 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2010135014A1 (en) 2009-02-27 2010-11-25 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
BRPI1014572B8 (pt) * 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US20130018039A1 (en) 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011149874A2 (en) 2010-05-26 2011-12-01 Schering Corporation N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
ES2536319T3 (es) 2010-11-30 2015-05-22 Takeda Pharmaceutical Company Limited Compuestos bicíclicos como inhibidores de acetil-CoA carboxilasa (ACC)
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
WO2013129674A1 (ja) 2012-03-01 2013-09-06 学校法人兵庫医科大学 新規ベンズイミダゾール誘導体及びその用途
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2013180193A1 (ja) 2012-05-31 2013-12-05 住友化学株式会社 縮合複素環化合物
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
TWI646099B (zh) 2012-11-01 2019-01-01 英塞特控股公司 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
WO2014153529A1 (en) 2013-03-22 2014-09-25 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
WO2014182954A1 (en) 2013-05-08 2014-11-13 Colorado Seminary, Which Owns And Operates The University Of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
HUE033587T2 (hu) 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
AU2014291142B2 (en) 2013-07-17 2018-10-11 Otsuka Pharmaceutical Co., Ltd. Cyanotriazole compounds
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SI3129021T1 (sl) 2014-04-08 2021-07-30 Incyte Corporation Zdravljenje malignosti B-celic s kombinacijo zaviralcev JAK in PI3K
EP2930048A1 (en) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Head up display projecting visual information onto a screen
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
BR112017005128A2 (pt) 2014-09-16 2018-07-31 Celgene Quanticel Res Inc inibidores de histona desmetilase
EP3209665B1 (en) * 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
PT3371190T (pt) 2015-11-06 2022-07-08 Incyte Corp Compostos heterocíclicos como inibidores de pi3k-gamma
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
CN109937038A (zh) 2016-08-26 2019-06-25 田边三菱制药株式会社 双环式含氮杂环化合物
WO2018136754A1 (en) 2017-01-20 2018-07-26 Massachusetts Institute Of Technology Injectable polymer micro-depots for controlled local drug delivery
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
JP2021500334A (ja) 2017-10-18 2021-01-07 エピザイム，インコーポレイティド Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
ES3039587T3 (en) 2017-12-21 2025-10-22 Basf Se Pesticidal compounds
HRP20230400T1 (hr) 2017-12-21 2023-06-23 Boehringer Ingelheim International Gmbh Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
WO2000053595A1 (en) 1999-03-06 2000-09-14 Astrazeneca Ab Pyrimidine compounds
WO2001014402A1 (en) 1999-08-19 2001-03-01 Isis Pharmaceuticals, Inc. Antisense modulation of focal adhesion kinase expression
WO2001064655A1 (en) 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003099771A2 (en) 2002-05-29 2003-12-04 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2004046120A2 (en) 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases
WO2004056786A2 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivates for the treatment of abnormal cell growth
US20050009832A1 (en) * 2003-02-20 2005-01-13 Sugen, Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004080980A1 (en) 2003-03-14 2004-09-23 Novartis Ag 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005028444A1 (en) 2003-09-24 2005-03-31 Novartis Ag 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
WO2006056399A2 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
WO2009064835A1 (en) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009114512A1 (en) 2008-03-11 2009-09-17 Incyte Corporation Azetidine and cyclobutane derivatives as jak inhibitors
WO2013104610A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
WO2016064957A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
WO2016166239A1 (en) * 2015-04-16 2016-10-20 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
WO2016183094A1 (en) 2015-05-12 2016-11-17 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS

Non-Patent Citations (57)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
A. KEREKES, J. MED. CHEM., vol. 54, 2011, pages 201 - 210
ALAN F. THOMAS: "Deuterium Labeling in Organic Chemistry", 1971, APPLETON-CENTURY-CROFTS
BARBER ET AL., NAT. MEDICINE, vol. 9, 2005, pages 933 - 935
BEROD ET AL., EURO. J. IMMUNOL., vol. 41, 2011, pages 833 - 844
BROCK ET AL., J CELL BIOL., vol. 160, no. l, 2003, pages 89 - 99
BUCHWALD, S. L.; RUIZ-CASTILLO, P., CHEM. REV., vol. 116, 2016, pages 12564
BUESKING, A. W.; BACAUANU, V.; CAI, I.; ELLMAN, J. A., J. ORG. CHEM., vol. 79, 2014, pages 3671
CAMPS ET AL., NAT. MEDICINE, vol. 11, 2005, pages 939 - 943
CANTLEY, SCIENCE, vol. 296, no. 5573, 2002, pages 1655 - 7
CARTER ET AL., CANCER BIOL. THER., vol. 10, 2010, pages 582 - 587
COMERFORD ET AL., PLOS ONE, vol. 7, 2012, pages e45095
DOUKAS ET AL., J. PHARMACOL. EXP THER., vol. 328, 2009, pages 758 - 765
DOUKAS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 19866 - 19871
EL KHOURY ET AL., NAT. MED., vol. 13, 2007, pages 432 - 438
FALASCA; MAFFUCCI, FRONTIERS IN PHYSIOLOGY, vol. 5, 2014, pages 1 - 10
GIRI ET AL., AM. J. PHYSIOL. CELL PHYSIOL., vol. 289, 2005, pages C264 - C276
GONZALEZ-GARCIA ET AL., GASTROENTEROLOGY, vol. 138, 2010, pages 1373 - 1384
HANAHAN; WEINBERG, CELL, vol. 144, 2011, pages 646 - 674
HAYER ET AL., FASB J., 2009, pages 4288 - 4298
J. LABEL COMPD. RADIOPHARM, vol. 55, 2012, pages 467 - 469
J. MED. CHEM., vol. 46, 2003, pages 2494 - 2501
JAMES R. HANSON: "The Organic Chemistry of Isotopic Labelling", 2011, ROYAL SOCIETY OF CHEMISTRY
JENS ATZRODT; VOLKER DERDAU; THORSTEN FEY; JOCHEN ZIMMERMANN, ANGEW. CHEM. INT. ED., 2007, pages 7744 - 7765
JIMENEZ ET AL., J BIOL CHEM., vol. 277, no. 44, 2002, pages 41556 - 62
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 55, no. 13, 2012, pages 467 - 469
JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2
K. BLOM: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM., vol. 4, 2002, pages 295
K. BLOM; B. GLASS; R. SPARKS; A. COMBS: "Preparative LCMS Purification: Improved Compound Specific Method Optimization", J. COMB. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOM; B. GLASS; R. SPARKS; A. COMBS: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOM; R. SPARKS; J. DOUGHTY; G. EVERLOF; T. HAQUE; A. COMBS: "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. COMBI. CHEM., vol. 5, 2003, pages 670
KANEDA ET AL.: "Abstract 3650", CANCER RES., vol. 74, no. 19
KOLB, H.C.; VANNIEUWENHZE, M.S.; SHARPLESS, K.B., CHEM. REV., vol. 94, 1994, pages 2483 - 2547
LAFFARGUE ET AL., IMMUNITY, vol. 16, 2002, pages 441 - 451
LI ET AL., NEUROSCIENCE, vol. 253, 2013, pages 89 - 99
LUPIA ET AL., AM. J. PATHOLOGY, vol. 165, 2004, pages 2003 - 2011
MARTIN ET AL., CANCER CELL, vol. 19, 2011, pages 805 - 813
MESSAOUDI, S. ET AL., ACS CATAL., vol. 5, no. 2, 2015, pages 1386
MORENO-DORADO, F.J.; GUERRA, F.M.; ORTEGA, M.J.; ZUBIA, E.; MASSANET, G.M., TETRAHEDRON: ASYMMETRY, vol. 14, 2003, pages 503 - 510
ORG. SYN. COLL., vol. 1, 1941, pages 289,131
ORG. SYN. COLL., vol. 1, 1941, pages 321
PASSOS ET AL., BRAIN BEHAV. IMMUN., vol. 24, 2010, pages 493 - 501
PINHO ET AL., L. LEUKOCYTE BIOLOGY, vol. 77, 2005, pages 800 - 810
PRETE ET AL., THE EMBO JOURNAL, vol. 23, 2004, pages 3505 - 3515
R. XU, J. LABEL COMPD. RADIOPHARM., vol. 58, 2015, pages 308 - 312
RANDIS ET AL., EUR. J. IMMUNOL, vol. 38, 2008, pages 1215 - 1224
RODRIGUES ET AL., J. NEUROIMMUNOL., vol. 222, 2010, pages 90 - 94
RUCKLE ET AL., NAT. REV. DRUG DISCOVERY, vol. 5, 2006, pages 903 - 918
SCHMID ET AL., CANCER CELL, vol. 19, 2011, pages 715 - 727
SCHMIDT ET AL.: "Abstract, 411", CANCER RES., vol. 72, no. 1, 2012
SHARPLESS, K.B.; AMBERG, W.; BENNANI, Y.L.; CRISPINO, G.A.; HARTUNG, J.; JEONG, K.-S.; KWONG, H.-L.; MORIKAWA, K.; WANG, Z.-M.; XU, J. ORG. CHEM., vol. 57, 1992, pages 2768 - 2771
SUBRAMANJAM ET AL., CANCER CELL, vol. 21, 2012, pages 459 - 472
SYNTHESIS, vol. 10, 1975, pages 617 - 630
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY & SONS, INC.
THOMAS ET AL., EUR. J. IMMUNOL., vol. 35, 2005, pages 1283 - 1291
VANHAESEBROECK ET AL., TRENDS BIOCHEM SCI., vol. 30, no. 4, 2005, pages 194 - 204
VECCHIONE ET AL., J. EXP. MED., vol. 201, 2005, pages 1217 - 1228

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12516065B2 (en) 2017-10-18 2026-01-06 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US12365668B2 (en) 2018-03-08 2025-07-22 Incyte Corporation Aminopyrazine diol compounds as PI3K-y inhibitors
US12421197B2 (en) 2018-07-02 2025-09-23 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN113677683A (zh) * 2018-09-05 2021-11-19 因赛特公司 磷酸肌醇3激酶(pi3k)抑制剂的结晶形式
EP3847175A4 (en) * 2018-09-05 2022-05-11 Incyte Corporation CRYSTALLINE FORMS OF AN INHIBITOR OF PHOSPHOINOSITIDE-3-KINASE (PI3K)
EP4338801A3 (en) * 2018-09-05 2024-06-05 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
AU2019336675B2 (en) * 2018-09-05 2024-09-26 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
US12173006B2 (en) 2018-09-05 2024-12-24 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
CN113677683B (zh) * 2018-09-05 2025-01-14 因赛特公司 磷酸肌醇3激酶(pi3k)抑制剂的结晶形式
JP2021165246A (ja) * 2020-04-08 2021-10-14 国立大学法人 名古屋工業大学 ペンタフルオロエチル基含有アルコール類の製造方法、有機半導体材料および酵素活性阻害剤の製造中間体化合物
WO2025031468A1 (zh) 2023-08-09 2025-02-13 江苏恒瑞医药股份有限公司 杂芳基化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CR20200214A (es) 2020-07-25
HUE056615T2 (hu) 2022-02-28
CN118063470A (zh) 2024-05-24
LT3697789T (lt) 2021-12-10
IL295978B1 (en) 2023-09-01
JOP20200086B1 (ar) 2024-04-18
EP3697789B1 (en) 2021-09-29
US10738057B2 (en) 2020-08-11
KR20200089264A (ko) 2020-07-24
GEP20237483B (en) 2023-03-27
ECSP20024651A (es) 2020-06-30
MA50398B1 (fr) 2021-10-29
RS62818B1 (sr) 2022-02-28
EP3697789A1 (en) 2020-08-26
IL273983B (en) 2022-10-01
PE20210169A1 (es) 2021-01-29
TW202340200A (zh) 2023-10-16
KR102717072B1 (ko) 2024-10-15
US20240228498A1 (en) 2024-07-11
JP7244504B2 (ja) 2023-03-22
IL273983B2 (en) 2023-02-01
IL273983A (en) 2020-05-31
JP2021500340A (ja) 2021-01-07
CN111542526B (zh) 2024-01-09
US11926630B2 (en) 2024-03-12
CY1124814T1 (el) 2022-11-25
JOP20200086A1 (ar) 2020-04-30
US20190152975A1 (en) 2019-05-23
PL3697789T3 (pl) 2022-02-21
SG11202003428VA (en) 2020-05-28
GEP20257716B (en) 2025-01-27
CL2020001047A1 (es) 2020-08-28
US20220213107A1 (en) 2022-07-07
AU2023203088A1 (en) 2023-06-15
CR20210442A (es) 2021-12-20
EP4006034A1 (en) 2022-06-01
TWI803525B (zh) 2023-06-01
JP2023085290A (ja) 2023-06-20
HRP20211827T1 (hr) 2022-03-18
MA50398A (fr) 2021-05-05
IL295978B2 (en) 2024-01-01
SI3697789T1 (sl) 2022-04-29
SA520411783B1 (ar) 2024-05-12
TWI834560B (zh) 2024-03-01
SMT202100656T1 (it) 2022-01-10
AU2018350980B2 (en) 2023-02-23
TW201927788A (zh) 2019-07-16
JP7541594B2 (ja) 2024-08-28
CA3084589A1 (en) 2019-04-25
BR112020007593A2 (pt) 2020-09-24
KR20240152947A (ko) 2024-10-22
GEAP202416013A (en) 2024-08-26
IL295978A (en) 2022-10-01
ZA202201220B (en) 2023-03-29
ES2902390T3 (es) 2022-03-28
GEAP202215327A (en) 2022-10-10
UA128085C2 (uk) 2024-04-03
US11225486B2 (en) 2022-01-18
AU2024287193A1 (en) 2025-01-23
US20200385392A1 (en) 2020-12-10
MX2020003862A (es) 2020-08-13
PT3697789T (pt) 2021-12-31
AU2018350980A1 (en) 2020-04-30
PH12020550442A1 (en) 2021-05-31
AU2023203088B2 (en) 2024-10-03
CN111542526A (zh) 2020-08-14
US12516065B2 (en) 2026-01-06
MD3697789T2 (ro) 2022-02-28
AU2018350980C1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
US12516065B2 (en) Tertiary alcohols as PI3K-γ inhibitors
EP3762368B1 (en) Aminopyrazine diol compounds as pi3k-y inhibitors
HK40075013A (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
HK40036959A (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
HK40036959B (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
EA043981B1 (ru) ТРЕТИЧНЫЕ СПИРТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-γ
EA049371B1 (ru) ТРЕТИЧНЫЕ СПИРТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kg

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18797408

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3084589

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020521911

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018350980

Country of ref document: AU

Date of ref document: 20181017

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2020/0005592

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 15327

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 2018797408

Country of ref document: EP

Effective date: 20200518

WWP Wipo information: published in national office

Ref document number: NC2020/0005592

Country of ref document: CO

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020007593

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020007593

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200416

ENP Entry into the national phase

Ref document number: 16013

Country of ref document: GE

WWG Wipo information: grant in national office

Ref document number: NC2020/0005592

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 522440438

Country of ref document: SA

WWR Wipo information: refused in national office

Ref document number: 522440438

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 11202003428V

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202003428V

Country of ref document: SG